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1.1. English Abstract 
Background: The abdominal aortic aneurysm (AAA) is a pathological dilatation of the aorta. Due to 
frequent lack of symptoms AAA often is not diagnosed in time which may lead to life-threatening 
rupture. To date, screening is based largely on ultrasound and computed tomography. There is need for 
diagnostic and prognostic markers in order to predict progression and risk of rupture. Furthermore, 
pharmaceutical treatment is required to develop alternatives to surgical intervention.  
Aim: Mouse models of AAA demonstrated that neutrophil extracellular traps (NETs) take part in the 
pathogenesis of AAA. Therefore, the aim of this study was to evaluate the prognostic marker potential 
of parameters indicating NETosis in patients with AAA throughout a monitoring period as well as pre- 
and post-surgical repair. In a second step, the therapeutic potential of inhibiting NETosis was tested in 
an experimental AAA mouse model.  
Methods: 7 AAA patients undergoing an elective aneurysm repair and 5 AAA patients still in the pre-
surgical monitoring process were evaluated. Peripheral blood was drawn and analyzed by ELISA for 
plasma levels of DNA-histone-complexes, myeloperoxidase, myeloperoxidase-histone complexes and 
citrullinated histone 3. Regarding the mouse model, the in vivo toxicity and optimal dosage of the 
selective NET inhibitor, GSK484, was evaluated in male ApoE KO mice. On day 0 an angiotensin II-loaded 
osmotic pump was implanted to induce AAA. From day 14 onwards either 200 µl buffered saline (5 
controls) or 2.0 µg GSK484 in 200 µl saline/g body weight (n=5) were applied daily via an intravenous 
port for a period of 2 weeks. Aneurysm progression was controlled by ultrasound. Confocal microscopy 
images of blood smears, stained for DNA, a neutrophil surface marker and citrullinated histone 4, were 
analyzed for the frequency of NETs.  
Results and Conclusion: In AAA patients in the monitoring phase plasma levels of citrullinated histone 
H3 correlated negatively with progression, i.e., low levels predicted fast progression over the next 6 
months. However, NET parameters in blood decreased significantly after surgery. These findings 
support the notion that NETs are involved in the pathogenesis of AAA but may have limited potential as 
clinical AAA markers. In the experimental AAA model the NET inhibitor GSK484 was administered in 
established disease and reduced the NETosis reactivity significantly. Nevertheless, GSK484 had no 
impact on disease progression. Further studies on the pharmaceutical potential of NETosis inhibitors 




1.2. Deutsche Zusammenfassung 
Hintergrund: Das abdominelle Aortenaneurysma (AAA) ist eine pathologische Erweiterung der Aorta. 
Die Erkrankung verläuft in den meisten Fällen asymptomatisch, wird folglich oft nicht rechtzeitig 
diagnostiziert und kann im Fall einer Ruptur zu lebensbedrohlichen inneren Blutungen führen.  
Momentan basieren die einzigen Detektionsverfahren auf Ultraschall oder Computertomographie. Für 
die Evaluation der Progression und des Rupturrisikos sind bis jetzt noch keine Blutparameter etabliert. 
Die einzige effektive Behandlungsmöglichkeit ist die chirurgische Sanierung. Da diese Eingriffe ebenfalls 
ein Risiko darstellen, ist es wichtig eine medikamentöse Behandlung zu entwickeln.  
Zielsetzung: In Tiermodellen für AAA konnte gezeigt werden, dass „neutrophile extrazelluläre Traps“ 
(NETs) eine Rolle in der Pathogenese dieser Erkrankung spielen. Das Ziel dieser Studie war es daher, 
Laborparameter, die die Bildung von NETs anzeigen, in AAA Patienten unter Progression zu messen 
sowie vor und nach der Operation zu analysieren. In einem experimentellen AAA Tiermodell wurde 
untersucht, ob durch Hemmung der NETose auch die Progression des AAA vermindert werden kann.  
Methoden: Von 5 AAA Patienten in der Monitoring (präoperativen) Phase und 7 AAA Patienten nach 
einer elektiven Aneurysma-Operation wurde peripheres Vollblut abgenommen und mehrere NETose 
Parameter wie DNA-Histon Komplexe, Myeloperoxidase-Histon Komplexe, Myeloperoxidase und 
citrulliniertes Histon 3 mittels ELISA im Plasma bestimmt. In einem AAA Tiermodell wurde das 
therapeutische Potential des selektiven NET Inhibitors GSK484 getestet. Männlichen ApoE KO Mäusen 
wurde  Angiotensin II via osmotischer Pumpe verabreicht, was die AAA Bildung auslöste. Ab Tag 14 
wurde für weitere 14 Tage die tägliche Behandlung mit entweder 200 µl gepufferter Saline (Kontrollen; 
n=5) oder 2.0 µg GSK484 in 200 µl Saline/g Körpergewicht (n=5) über einen intravenösen Port 
durchgeführt. Die Aorta wurde mittels Ultraschall vermessen. Von jedem Tier wurde am Ende der 
Behandlung ein Blutausstrich angefertigt. Dieser wurde auf DNA, einen neutrophilen 
Oberflächenmarker und citrulliniertes Histon 4 angefärbt; NETs wurden in Konfokal-
mikroskopieaufnahmen ausgezählt.  
Ergebnisse und Schlussfolgerung: In der präoperativen Monitoring Phase zeigten die Blutwerte für 
citrulliniertes Histon H3 eine negative Korrelation mit dem Aneurysmawachstum, d.h. niedrige Werte 
konnten eine rasche Progression vorhersagen. Jedoch waren die NET Parameter im Patientenblut 
postoperativ signifikant reduziert. Somit untermauern diese Daten, dass NETs eine Rolle in der 
Pathogenese des AAA spielen, jedoch scheinen sie als klinische Marker begrenztes Potenzial zu haben. 
Im Tiermodell bewirkte die Applikation des NET Inhibitors, GSK484,  eine signifikante Verminderung der 
NETose Kapazität, nicht aber der AAA Progression. Diese Ergebnisse lassen darauf schließen, dass 






The abdominal aortic aneurysm (AAA) is an arterial, focal dilation of the aortic wall. It is defined to have 
a diameter of ≥3.0 cm or a diameter being at least 1.5 times larger than an aorta from a healthy 
individual [1]. 
 
All three parts of the arterial wall - adventitia, media and intima - are involved in the pathogenesis of 
the so called “aneurysm verum”. With over 80% the main localization of the AAA is below the renal 
artery (infrarenal) [1]. The aneurysm is one of the main diseases of the aorta. Over time aneurysms tend 
to dilate, with larger ones progressing faster [2]. They are associated with a high morbidity and mortality 
due to life-threatening bleedings after rupture [3].  
2.2.  Epidemiology 
The overall prevalence mainly among men for the AAA is about 4-6% at the age of 65-80 [4]. Therefore 
it is higher than the 0.5-1.3% prevalence in women of the same age group [5]. It is assumed that women 
may be protected by their sex hormones, but the underlying mechanism is still not fully understood [6].  
However, women tend to have a worse prognosis due to an increased risk of rupture [7]. The annual 
new AAA diagnoses rate is approximately 0.4 to 0.67% in the Western populations, which is equivalent 
to 4 to 6.7 aneurysms per 1000 persons per year [8]. 
The formation of the AAA is highly dependent on the age. An incidence of acute events affecting the 
aorta, like rupture or acute severe pain in the abdomen and/or back, increased to 55 per 100.000 
persons per year in the 65- to 74-years-old age group and up to 298 per 100.000 persons per year in the 
above 85-years-old age group. Thus the risk is increasing constantly with the years of life with 66.0% of 
all events occurring at age ≥75 years [9]. Ruptured AAAs are responsible for 1-2% of all deaths in men 
above 65 years. Half of the deaths are occurring before the patient reaches the hospital. Still 30-70% of 
patients die after being admitted for emergency treatment. Therefore, the overall mortality rate is 65% 
-85% [10]. 
2.3. Risk Factors 
The “Southern Community Cohort Study” evaluated 18782 participants of ≥65 years of age living in the 
USA. After 4.94 years of observation, 281 cases of AAA were identified. It was shown that the major risk 
factors for development are male gender, age and (in both sexes) smoking [11]. Minor risk factors are a 
positive family history, Caucasian race, a previous myocardial infarction, hypertension, 
hypercholesterolemia, atherosclerosis, presence of additional vessel aneurysms, cerebrovascular 
insufficiency, peripheral arterial disease and coronary arterial disease [12-14]. Also genetic tissue 
conditions like Marfan syndrome and Ehlers-Danlos syndrome are associated with an increased risk for 
developing an AAA [15]. 
Tobacco smoking is one of the main risk factors for AAA development and progression [16]. Twentytwo 
percent of screened patients in the USA, diagnosed with AAA, are current smokers and 36.9% are former 
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smokers. Therefore, nearly two thirds of AAA patients are exposed to tobacco smoke [17]. The odds for 
developing an AAA are positively associated with the number of pack years [18]. Men consuming more 
than 25 cigarettes per day have a 15-fold risk of developing an AAA when compared to non-smokers. 
Even after quitting the risk remains elevated, which indicates that the adverse effects induced by 
tobacco smoking are irreversible [19]. Current tobacco smoking results in an increased AAA growth of 
0.05 cm per year [20] and a two-fold elevated risk of rupture [12]. Tobacco promotes AAA formation 
through triggering inflammation, proteolysis and apoptosis of smooth muscle cells (SMCs) due to the 
ability of nicotine to stimulate matrix metalloproteinase (MMP) expression [21]. Furthermore, chronic 
nicotine exposure results in higher release of pro-inflammatory cytokines by macrophages [22], as 
discussed in detail in section 6. 
An increase in diastolic blood pressure per 10 mm Hg is associated with an enhanced growth rate of 
0.02 cm per year [20]. Another study did not confirm the association between hypertension and 
progression of the aortic diameter, but described a positive correlation between hypertension and the 
risk of rupture [23]. 
2.4. Protective Factors 
Non-Caucasian race, female gender [24], moderate ethanol consumption [19] and diabetes type II [20] 
have been considered as factors reducing the risk of AAA formation.  
The protective effect of diabetes seems to be paradox. The exact biological mechanisms still remain 
unclear [25]. Diabetes mellitus is reportedly associated with a reduced mean AAA growth rate of 0.11 
cm per year (standard deviation of 0.02 cm/year) [20]. Recently, a study suggested that not diabetes 
itself, but the oral antidiabetic metformin protects against AAA formation [26].  
In addition, a healthy lifestyle consisting of physical activity and frequent consumption of fruits, nuts 
and vegetables reduces the risk of developing an AAA [16]. 
2.5. Histology 
The aortic wall is composed of the tunica intima, media and the adventitia. The intima is formed by a 
thin layer of endothelial cells, subendothelial connective tissue and the internal elastic lamina. The 
media is composed of layers of vascular smooth muscle cells (VSMCs) and extracellular matrix (ECM). 
The adventitia consists of connective tissue containing the vasa vasorum and nerves [27].  
Collagen and elastin fibers are mainly responsible for the mechanical properties. Their main function is 
opposing the force of blood pressure to preserve the structural integrity. Elastin fibers occur more often 
in the tunica media. Collagen fibers, especially collagen type I and III, are more abundant in the tunica 
media and tunica adventitia [28].   
The AAA is organized spatially. The lumen is often filled with a multilayered, hemoglobin-rich 
intraluminal thrombus (ILT), followed by a thinned and degraded media and an inflamed and/or fibrotic 
adventitia [29]. In the atherosclerotic AAA the intima is thickened due to necrotic, lipid-enriched plaque 
formation. It is also observed that inflammatory cells, like macrophages and lymphocytes, infiltrate the 
adventitia and media of the aorta [30]. During the progression of disease the media is thinning and the 
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number of SMCs is decreasing [31]. In addition, the amount of elastin is reduced and the configuration 
of the fibers is distorted [32]. 
In addition, hem- and lymphangiogenesis are increased in the aneurysm wall. The expression of vascular 
endothelial growth factor receptor in the microvessels is elevated. In this area degradation and 
infiltration of inflammatory cells are more prominent [33]. Furthermore, it has been observed that the 
number of capillaries and thick-walled vessels are increased in the adventitia. These vessels are often 
surrounded by inflammatory infiltrates, mostly macrophages and lymphocytes [34].  
The thrombus structure was reported to be inhomogeneous. The luminal side is composed of densely 
packed fibrin. This side is being invaded by leukocytes and erythrocytes [35]. On the contrary, the medial 
and abluminal parts are being exposed to fibrinolysis resulting in decreased stiffness. These parts of the 
thrombus contain a network of interconnected canaliculi functioning as a transport system for 
macromolecular particles [36]. Recently, three subtypes of ILT were identified based on their 
morphology and mechanical properties. The first type, representing the majority of ILTs, showed a 
decrease in strength and stiffness from the luminal to abluminal side. However, all three layers of the 
ILT were mostly intact - a distinct luminal and thick medial and abluminal layer. In the second type a loss 
of mechanical resistance from the luminal to the medial/abluminal part was observed. A thinning and 
enhanced degradation of the outer vessel wall was described. In a few cases a third type of thrombus 
was reported, characterized by an almost fluid-like consistency [37]. However, it has not been 
documented whether these subtypes promote/interfere with the progression of the disease or 
influence the risk of rupture.   
2.6.  Pathogenesis  
AAA formation is characterized by a loss of stability of the aortic wall due to defect smooth muscle cells, 
smooth muscle cell apoptosis, inflammation, upregulation of proteolytic pathways, matrix degradation, 
formation of an intraluminal thrombus and many other factors [30, 31, 38-42]. 
2.6.1. Smooth Muscle Cells 
The media of the abdominal aorta contains vascular smooth muscle cells. This cell type has numerous 
functions like synthesis of matrix, the inhibition or activation of proteases and the recruitment of 
inflammatory cells. Thus, SMCs play an important part in keeping the homeostasis of the aortic matrix 
[40].  
SMCs of the descending aorta derive from the embryonal paraxial mesoderm somites, while SMCs in 
the aortic root, ascending aorta and the aortic arch derive from the neural crest, a part of the ectoderm 
[39]. It is assumed that the different origins may influence the formation of certain vascular diseases 
[43].  
The SMCs of AAA patients differ in their gene expression in comparison to the ones of healthy individuals 
[40]. It has been shown that they have an elevated proteolytic activity, i.e. in comparison to non-AAA 
SMCs these cells show increased MMP-9 expression due to post-transcriptional failure of MMP-9 
synthesis control. These findings suggest that SMCs from AAA patients take part actively in the 
degradation of the matrix resulting in weakening of the media [40]. It has been observed that these 
alterations in gene expression occur even before the aneurysm has developed [44].  
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SMCs express low density lipoprotein receptor protein 1 (LRP1), which may be linked to the formation 
of AAA [45]. One of the functions of this protein is to maintain the integrity of the vessel through 
regulating protease activity and ECM deposition [46]. However, it has been reported recently that in 
mice, treated with angiotensin II, deficiency for LRP1 does not influence the AAA formation [47]. 
The AAA is characterized by a  depletion of medial SMCs due to apoptosis [48].  However, it still remains 
unclear whether the cell death is an active pathological event or a result of tissue deterioration [47]. 
 
2.6.2. Hemodynamic Pressure 
At the point of the aortic bifurcation hemodynamic turbulences may occur resulting in an 
inhomogeneous pressure on the endothelial layer of the vessel. In case of the infrarenal aorta, elevated 
hemodynamic pressure leads to the deregulation of proteins which take part in AAA formation, and in 
turn, due to the decrease of elastin in the media along the length of the aorta the stiffness of the wall 
becomes higher and therefore the amplitude of the pulse waves are increasing [49].  
Due to hemodynamic turbulences the endothelial NO synthase may become uncoupled leading to an 
increased production of NO, which may give rise to the generation of peroxynitrite [50]. Peroxynitrite is 
turning pro-MMPs, the inactive zymogens, to the active state [51]. As a result of this endothelial 
dysfunction, the endothelial cells produce more MMP-2 and MMP-9, which contribute to the adaptive 
remodeling due to their ability to change the tissue architecture in the vessel wall [52, 53]. In addition, 
elevated shear stress results in the secretion of factors like transforming growth factor beta or fibroblast 
growth factor-2 by endothelial cells which may again induce the production of MMPs by SMCs [54, 55].  
2.6.3. Inflammation 
2.6.3.1. Role of Neutrophils 
The luminal part of the ILT contains many neutrophilic granulocytes and other polymorphonuclear cells 
(PMNs). Neutrophils use nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and 
myeloperoxidase (MPO) for pro-oxidant activities [56]. To be specific, NADPH oxidase catalyzes the 
production of superoxide free radicals, which may give rise to the secondary generation of different 
reactive oxygen (ROS) or nitrogen species (RNS). MPO is expressed also in 95% of PMNs [56, 57]. 
Compared to healthy individuals, the blood from AAA patients contains PMNs with less catalase activity 
indicating reduced anti-oxidative capacities. Furthermore, PMNs from AAA patients express significantly 
more hydrogen peroxide and MPO than healthy controls [58]. These observations lead to the conclusion 
that increased oxidative stress could be one of the main factors in AAA pathogenesis [58].  
Neutrophilic granulocytes play a key role in the pathogenesis of AAA by contributing not only to a pro-
oxidant state but also to the proteolytic degradation of the media in the aortic wall and to the  
inflammation of the adventitia [29]. Accordingly, PMN depletion inhibits significantly AAA formation in 
a rodent model [59]. Their recruitment to the luminal part of the ILT may be due to the release of 
interleukin-8 (IL-8), a neutrophil chemotactic factor, which is increased considerably in AAA patients 
[60]. One source of IL-8 may be neutrophil extracellular traps (NETs) [61]. The expression of leukotriene 
B4, another neutrophil chemotactic factor, is also elevated in the luminal layer of the ILT [62]. In 
addition, the alternative complement pathway is activated in AAA, as confirmed by a murine model in 
which the formation of AAA is reportedly depended on the activation of this system [63].  
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2.6.3.2. Role of Macrophages 
Macrophages play an important role in the pathogenesis of AAA. These cells are able to polarize into 
various phenotypes, i.e. the classically activated or the alternatively activated phenotype. Classically 
activated macrophages produce pro-inflammatory cytokines promoting tissue degradation, while 
alternatively activated macrophages are associated with tissue repair. In AAA there is an imbalance 
between these two phenotypes in favor of the classically activated macrophages [38]. 
Macrophages can be found in every part of the aortic wall but tend to accumulate mostly in the 
adventitia and the ILT [64, 65]. They are attracted most probably by ECM degradation products and 
various chemokines. Accordingly, it has been shown that chemotactic proteins like IL-8, tumor necrosis 
factor alpha (TNF-α) and monocyte chemotactic protein-1 are co-localized with infiltrating macrophages 
[66, 67].  
Macrophages promote the disease by the release of pro-inflammatory cytokines such as TNF-α, IL-6, IL-
1β, and interferon gamma [68, 69]. Furthermore, macrophages produce chemokines like CXCL1 leading 
to the recruitment of neutrophils, which further express pro-inflammatory cytokines like IL-6 [70]. It has 
been shown that elevated levels of IL-6 promote differentiation into activated macrophages again 
leading to an increased recruitment of monocytes to the aortic wall and enhancing further disease 
progression [71]. Thus, the recruited macrophages trigger a positive feedback loop supporting the 
development of chronic inflammation [38]. 
2.6.4. Degradation of Extracellular Matrix 
Within the aortic wall the extracellular matrix is produced by SMCs, endothelial cells and fibroblasts 
[72]. The matrix contains amongst other proteins collagen, glycoproteins and elastin [73]. The AAA is 
characterized by a progressive dilatation of the abdominal aorta triggered by the degradation of ECM 
by proteolysis [74]. In general three classes of proteases are mainly responsible for matrix degradation: 
cathepsins, elastases, and MMPs [41, 75].  
Deficiency of cathepsin K may attenuate the development of AAA, as shown in an experimental model 
of elastase-induced AAA [76]. MMPs disrupt and fragment the elastin lamellae and collagen in the 
extracellular matrix of the aorta [77]. In AAA MMP activity is generally increased and their inhibition 
decreased, leading to an imbalance towards enhanced proteolytic activity [78]. Accordingly, in mice 










 In 70-80% of the cases an intraluminal thrombus (ILT) can be found in an AAA [37]. It has been observed 
that the thrombus may protect the aneurysm from rupturing due to the fact that peak wall stress 
induced by hypertension is being significantly reduced [80]. More recent studies show that the 
potentially protective mechanism depends on the kind of attachment of the thrombus to the aortic wall 
[81].  
A large thrombus, however, results in hypoxia in the underlying vessel wall. This process initiates 
adventitial angiogenesis and increases infiltration of inflammatory cells from the outer layers of the 
aortic wall leading to weakening of the wall [82]. Now the vessel wall is exposed to high concentrations 
of proteases, cytokines and reactive oxygen species further enhancing aneurysm formation. At the site 
of ILT localization SMC dedifferentiation and apoptosis occurs. It has been observed that the diameter 
of the AAA, MMP levels, SMC apoptosis and elastin degradation correlate with each other [42, 83].  
The development of an ILT does not only lead to the thinning of the arterial wall [82], reduction of SMC 
density in the media and inflammation in the adventitia but also to degradation of elastin fibers [83]. 
This shows that protease activity partly originates from the ILT. Within the ILT MMP-9 in pro- and active 
form [84] and MMP-9-lipocalin complexes can be found. These enzymes originate from neutrophils [85]. 
Especially in the luminal part of the ILT high levels of MMP-8, MMP-9 and elastase have been observed 
to co-localize with neutrophils [86]. Proteases secreted by neutrophils may degrade matrix fibrillary 
proteins over time leading to the progression and rupture of AAA. It has been shown that high levels of 
proteases [87], increased leukocyte infiltration and neovascularization [88] occur at the site of 
adventitial rupture.  
At the site of ILT, hemostasis and fibrin destruction are occurring continuously, leading to increased 
levels of coagulation and fibrinolysis factors in the blood of AAA patients and the tissue of the ILT [89]. 
Circulating fibrinogen, the fibrin degradation product D-dimer, and thrombin-antithrombin III complex 
correlate with the size of the AAA and ILT and have prevailed as diagnostic markers [90-92]. It has been 
reported that fibrinogen levels are elevated years before an AAA is formed. This indicates that 
deregulated hemostasis and fibrinolysis may be causally involved in AAA pathogenesis from an early 
stage onwards [93].  
 
2.7. Clinical Presentation 
Due to the lack of symptoms AAAs often remain undetected until rupture. They are frequently 
diagnosed by chance via ultrasound or abdominal palpation during a regular check-up [24]. 
In cases of symptomatic AAAs the patients suffer from diffuse pain in the back or abdomen. It is also 
possible that the ILT can lead to embolization. These cases should be treated electively by surgery due 






2.8. Screening and Treatment Indications  
In general, AAAs smaller than 5.5 cm expand about 2-3 mm per year. The expansion of larger AAAs is 
reported to be more rapid [13]. However, there are large interindividual variations. Most AAAs remain 
constant for quite some time and progress afterwards, some grow continuously and others remain 
stable [94].  
Small AAAs with a diameter of 3.0-3.9 cm carry nearly no risk of rupture within the next 12 months. The 
chance of rupturing for an AAA with the diameter of 4.0-4.9 cm is only 1% [13]. In these cases a strict 
surveillance via ultrasound or computed tomography (CT) is recommended. Men with an aneurysm 
diameter of 3.0-4.0 cm should be examined at regular intervals. If the diameter reaches 4.0-4.9 cm the 
check-up should take place every year. When the diameter is about 5.0-5.4 cm the interval should be 
shortened to 6 months [95]. Exact surveillance intervals for woman have not been established yet but 
are usually conducted comparable as for men.  
AAAs over 5.0 cm for women and 5.5 cm for men have an elevated risk of rupturing within the next 12 
months and therefore surgical intervention is recommended [13]. In case of rapidly expanding 
aneurysms, i.e. about 1 cm per year, early intervention is urgently required [13]. 
Not only the diameter, but also the AAA morphology is important for choosing whether surgical 
intervention is needed. AAAs exposed to high hemodynamic pressure and/or showing an intraluminal 
thrombus  are more prone to rupture [96]. It has been reported that symptomatic and ruptured AAAs 
are under more peak wall stress compared to asymptomatic ones. As a result earlier intervention is 
recommended for symptomatic AAAs [96]. 
 
2.8.1. Treatment  
2.8.1.1. Surgical Intervention  
In general there are two options for surgical treatment, i.e., open surgical repair (OSR) and endovascular 
repair (EVAR). The latter one is based on the placement of an expandable stent graft in the aorta through 
the femoral artery. Prior to the intervention computed tomography angiography (CTA) or magnetic 
resonance imaging (MRI)  are conducted in order to obtain information about the morphology of the 
AAA in case of OSR or for choosing the right stent graft in case of EVAR [13]. 
EVAR is the less invasive option and the intraoperative risk is lower. On the other hand it is only possible 
to conduct EVAR if the aorta and the iliac arteries are not kinked [13]. In up to 25%  of the patients the 
implanted stent is leaking [13] and therefore re-intervention occurs more often in EVAR (18.9%) [97]. In 
cases of high age and/or comorbidities, EVAR is the preferred method due to its lower intraoperative 
risk and better initial outcome [98, 99]. Complications include perioperative disseminated intravascular 
coagulation [100] and venous thrombosis despite heparin prophylaxis [101]. Meta-analyses have shown 
that OSR performed in elective AAAs  had a significantly higher 30-day mortality (3.2-4.2%) than EVAR 





2.8.1.2. Pharmacological Treatment  
Despite the fact that surgery is the only curative treatment, medical intervention is recommended in 
order to control comorbidities and slow down disease progression [56]. The guidelines of the “European 
Society for Vascular Surgery” recommend that AAA patients should be treated with statins to lower 
blood lipid levels and with low doses of acetylsalicylic acid, an inhibitor of cyclooxygenase 1 and 2, to 
prevent platelet aggregation [13]. The patients should start the treatment with statins one month prior 
to the intervention in order to minimize cardiovascular morbidity. The intake should be continued 
during the perioperative period. In addition, low-dose acetylsalicylic acid administration should be 
started at the point of diagnosis and should be continued throughout the perioperative period [13].  
It needs to be mentioned that only statins have been reported to reduce cardiovascular mortality and 
to slow down the progression of the disease. Other drugs like beta-blockers, angiotensin-converting 
enzyme inhibitors and angiotensin 1- receptor antagonists, which may be prescribed in order to treat 
comorbidities, do not reduce the growth of the AAA [103]. According to a clinical study a 50% reduction 
of the AAA expansion rate has been observed under statin treatment [104], an observation confirmed 
by a large meta-analysis [105, 106]. However, Golledge et al. observed similar growth rates in subjects 
prescribed (median 1.2 mm) and not prescribed statins (1.0mm) (p=0.226) [92]. With regard to the 
mode of action, the statin simvastatin reduces free radical formation and inflammatory molecules in 
the AAA wall by suppressing the NF-κB signaling pathway [107]. As a consequence, infiltrating T helper 
lymphocytes, SMCs and monocytes [108] release less of pro-inflammatory cytokines, like IL-6 and IL-8, 
and MMPs [109]. In fact, the reduction of experimental AAA development by 25% and the reduced 
incidence of AAA by 30% under statin therapy [110] are associated with a lower MMP-9 expression in 
the vessel wall [111].  
Animal models of cholesterol-fed rabbits suffering from atherosclerosis have demonstrated that aortic 
plaque size and thrombus formation may decrease significantly under therapy with acetylsalicylic acid 
[112]. A meta-analysis of randomized trials on primary and secondary prevention of vascular disease 
has shown that immediately after AAA diagnosis low-dose therapy with acetylsalicylic acid should be 
started due to potential reduction of vascular deaths [113]. It was recommended to proceed with the 
treatment lifelong in order to prevent cardiovascular complications like stroke, myocardial infarction or 
death [114]. On the other side, a retrospective aneurysm study on data from the National Health 
Insurance Research Database did not find any correlation between low-dose treatment with 
acetylsalicylic acid and mortality reduction [115]. 
Also neutrophilic granulocytes may serve as a therapeutic target. In a clinical trial the number of 
neutrophils in the aortic wall was reduced by preoperative doxycycline therapy resulting in an improved 
proteolytic balance [116]. In a further clinical study MMP-9 protein levels were 2.5-fold decreased under 
doxycycline treatment (100 mg orally twice a day for 7 days before surgery) indicating a potential 
pharmaceutical target [117]. In experimental animals - male Wistar rats whose abdominal aorta was 
perfused with porcine pancreatic elastase - the antibiotic doxycycline inhibited directly the activity of 
MMPs in neutrophils, suppressing elastase-induced AAA development [118]. In addition, a reduced 
number of cytotoxic T-cells in the aortic wall was observed as well [119]. However, clinical trials with 




2.9.  Surrogate Markers  
Up to date most AAAs are detected by chance. Therefore, current research aims to find predictors to 
detect early AAA, monitor the progression of this disease and to identify patients with high rupture risk. 
In general such disease markers could possibly be based on alterations in morphological features or 
parameters in blood.  
2.9.1. Morphological markers 
First, the determination of the maximal AAA diameter via ultrasound is the most common morphological 
surrogate marker for disease progression [121]. However, ultrasound results often vary in dependence 
of the observer [122] and the way the calipers are placed [121]. MRI and CTA show better 
reproducibility, are more accurate [123] but are not always available and entail higher costs. 
 
Alternatively, the assessment of AAA volume may obtain more reproducible data and may be a more 
sensitive progression marker [124]. This approach takes into consideration that the morphology of 
aneurysms is highly variable and that the overall size rather than the diameter is of importance. The 
volume may be measured by MRI, CTA and ultrasound [125, 126]. Nonetheless, until now no exact 
volume (cut-off value) could be determined, serving as indication for surgical intervention [127].  
 
Third, the formation, morphology and the size of an intraluminal thrombus (ILT) may be used as a 
marker. As outlined in section 2.6.5. the ILT is composed of many cell types, interacting with each other 
and leading to a progressive weakening of the aortic wall [102]. Accordingly, large ILTs lead to an 
accelerated formation and dilatation of AAA [124]. 
 
2.9.2. Functional markers  
 
Currently positron emission tomography combined with CT imaging (PET/CT) is used for functional 
imaging of the AAA. Labeling with 18-fluorodeoxyglucose (FDG) reveals that the glucose metabolism is 
elevated in areas of inflammation and cell proliferation. It has been reported that in AAA patients 
suffering from symptoms the FDG-uptake is increased [128]. On the other hand, asymptotic AAA 
patients do not show an increased FDG-uptake in the aortic wall [129]. 
 
Functional imaging via MRI enables to assess the composition of the aortic wall and the cellular activity. 
For example, the phagocytic activity of macrophages may be determined by applying the contrast agent 
superparamagnetic iron oxide. This technique has been established for patients suffering from AAA 
[130]. It was reported that the extent of iron oxide uptake in the aortic wall is dependent on the activity 
of macrophages and correlates with an increased AAA expansion rate [131]. This method has the benefit 
of not utilizing ionizing radiation and therefore enables repeated examination of AAA patients.  
 
2.9.3. Markers in blood 
 
Several blood parameters have been associated with the formation and progression of AAA, e.g., 
elevated D-dimer levels may indicate the remodeling of ILT and expansion of AAA [91], increased 
concentrations of MMP-9 are a surrogate for an enhanced proteolytic activity, high serum levels of the 
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type-III procollagen peptide may be a sign of collagen-turnover and AAA expansion [132] and elevations 
in IL-6 indicate inflammation [133]. 
To be specific, based on elevations in plasma D-dimer concentration it was possible to identify different 
progression rates in patients with an AAA. In men D-dimer levels lower than 150 ng/ml were associated 
with a median expansion rate of 0.7 mm per year whereas D-dimer levels over 900 ng/ml were 
associated with a median expansion rate of 1.7 mm per year [92]. In the last few years, the formation 
and progression of AAA was monitored with circulating micro-RNAs, such as miR-155, miR-191-3p, miR-
455-3p, miR-1281, and miR-411 [134]. Recent research indicates that factors released by neutrophilic 
granulocytes may serve as AAA markers, e.g., elevated levels of gelatinase-associated lipocalin were 
found in patient plasma and indicated activation of neutrophils and expansion of AAA [135]. Also 
elevated MPO and cell-free DNA levels correlated significantly with the diagnosis of AAA [135]. 
 
Hitherto, however, no blood-borne marker has been introduced into the clinical practice due to the 
limited sensitivity, specificity and prognostic value. 
 
 
2.10. Neutrophilic Granulocytes  
Neutrophilic granulocytes, also known as polymorphonuclear cells, are the most common white blood 
cells in the human blood [136, 137]. They take part in the first line of immune defense against various 
pathogens.  
Mature neutrophils leave the bone marrow and enter the circulation. Cytokines recruit PMNs to the site 
of inflammation by inducing the expression of E- or P- selectin on the surface of endothelial cells [138]. 
After interacting with these selectins, the neutrophils start to roll on the endothelium. PMNs may be 
chemotactically attracted and activated through IL-8, complement factors (C5a) or N-formyl-peptides 
from bacteria. This stimulation leads to the activation of integrins, which bind to cell adhesion molecules 
of the immunoglobulin superfamily (intercellular adhesion molecules) on the surface of the 
endothelium and keep neutrophils at this site. In case of a gradient of chemotactic cytokines, PMNs 
migrate through gaps in the endothelium into the inflamed tissue [137, 139]. The hypothesis that 
neutrophils are unable to return to the peripheral blood has been challenged by many studies 
demonstrating that the cells move back and reach different sites of the body, including secondary 
lymphoid tissues [140, 141]. 
Neutrophils are known to play an important role in AAA development. Accordingly, neutrophil depletion 
in mouse models inhibits AAA formation [59, 142]. In recent years, it has been shown that neutrophils 
can undergo a form of cell death called “NETosis” [139, 143]. This phenomenon has also been linked to 







2.11. Neutrophil Extracellular Traps  
In 2004 so called neutrophil extracellular traps (NETs) were first mentioned by Brinkmann et al. [143]. 
It was shown that NETs are derived from neutrophil granulocytes and are able to trap bacteria and 
degrade virulence factors locally by their enzymatic activity before the pathogens are engulfed by 
neutrophils or macrophages [143]. This process prevents dissemination of pathogens. This discovery 
offered new insight into the role of neutrophils in the innate immune response.   
     
2.11.1. Formation of NETs                                                                                 
 
NETs are web-like structures composed of discharged chromatin, histones, neutrophil elastase, 
myeloperoxidase, MMP-9, cathepsin G, gelatinase and several other proteins [143]. Scanning electron 
microscopy has shown that NETs contain smooth fibers with a diameter of 15 to 17 nm and globular 
domains with a diameter of about 25 nm. Through aggregation a larger thread is formed with a diameter 
of 50 nm [143]. Further research revealed that these threads are composed of thin and parallel fibers 
of a diameter smaller than 2 nm [145]. DNase can destroy NETs which is indirect evidence that DNA in 
chromatin is building the backbone of NETs [139]. About 70% of all proteins within NETs are the histones 
H2A, H2B, H3 and H4 [146]. The molecular mass of histones in NETs is larger than the ones in the nucleus 
due to posttranslational modification [146]. It was suggested that the modification is involved in the 
regulation of NET formation [147].  
The formation of NETs is triggered when neutrophils are overly activated [148] by a wide spectrum of 
stimuli, like lipopolysaccharides, bacteria, fungi, viruses, and parasites [143, 149, 150]. In addition, also 
endogenous, noninfectious stimuli like C5a, an important complement factor, lead to the release of 
NETs, after neutrophils have been primed with GM-CSF [151]. Depending on the dose of the activator 
more or less NETs are formed [143]. 
Within the first hour after being stimulated most neutrophilic granulocytes are involved in phagocytosis. 
Then about one third of the neutrophils changes the morphology and prepares for NET formation [139, 
150].  In this phase less phagocytosis is observed. A few hours later NETs are formed and from this point 
onwards most of the antimicrobial activity is NET-associated. In sum phagocytosis and NETs show similar 
effectiveness with regard to defense [150]. 
During the formation of NETs, the nucleus loses its lobules followed by decondensation of the chromatin 
and swelling [150]. The inner and outer nuclear membranes separate from each other. The nuclear 
envelope disintegrates into vesicles after about 2 hours; the nucleoplasm and cytoplasm are no longer 
separated. After a few hours neutrophils round up and contract until the cell membrane ruptures. Then 
neutrophils eject intracellular components into the extracellular space and NETs are formed. It appears 
that NETs are flexible structures surrounding the dying neutrophils. It is reported that the release does 
not occur due to apoptosis or necrosis. Therefore, NETosis marks a new form of cell death [150].  
It has been shown that macrophages are able to clear NETs after they have finished executing their 
function. This path is initiated when DNase I degrades the extracellular structures and the debris is 
opsonized with the complement factor C1q. As a result NETs are internalized by macrophages through 




2.11.2.  Molecular Pathways 
 
The formation of NETs is called NETosis [150, 153, 154]. Despite intense research the molecular 
pathways involved in this process are not fully understood and seem to be diverse.  
NETosis is promoted through the activation of protein kinase C (PKC) [155]. Research has shown that 
PKC plays a major role in regulating the citrullination of histones during NETosis, i.e., PKCζ may activate 
PAD4, an enzyme important for citrullination of arginine residues in histones. The resulting change in 
the charge of the histones enables chromatin decondensation [155, 156]. Also ROS production is 
important for NET formation. It is believed that ROS plays a role in the translocation of neutrophil 
elastase and MPO from the granules to the nucleus where they induce chromatin decondensation and 
histone degradation [150]. The role of ROS is confirmed by observations that inhibition of the NADPH 
oxidase (NOX) complex by diphenyleneiodonium (DPI) inhibits NETosis. Phorbol-12-myristate-13-
acetate (PMA), an activator for PKC and the Raf/MEK/ERK pathway, leads to increased ROS production 
and NET formation [156-158]. The Raf-MEK-ERK pathway has also been observed triggering NETosis and 
preventing apoptosis by regulating the expression of the anti-apoptotic protein Mcl-1 [158]. 
Another study observed that immobilized immune complexes (iICs) can trigger NETosis [159]. This 
mechanism is ROS dependent. Following ilCs stimulation, FcγIIIB and Mac-1 receptors on the surface of 
neutrophils are activated, which leads to a Syk-, PI3K/Akt-, and p38 MAPK-mediated signaling, causing 
NET formation and release [159]. 
Autophagy plays also an important part in NET generation. In most cells, including neutrophils, mTOR 
(mammalian Target of Rapamycin) kinase is the key autophagy regulator [160]. The mTOR pathway is 
able to coordinate intracellular cascades that lead to the activation of neutrophils and NET release. 
Accordingly, rapamycin, an antibiotic, used to inhibit mTOR kinase, leads to decreased NET formation 
[161]. These finding were confirmed by the PI3K inhibitor Wortmannin, a non-specific autophagy 
inhibitor, which was able to impair NETosis [162]. In addition, Wortmannin seems to be able to inhibit 
histone protein deimination, preventing neutrophils from forming NETs [160].  
Furthermore, it has been demonstrated that calcium-activated potassium channels are able to induce 
ROS-independent NETosis based on histone citrullination [163].  
In general, three different kinds of NETosis have been observed.  
Suicidal NETosis 
After about 2-3 hours of stimulation with PMA suicidal NETosis can be observed. NADPH oxidase (NOX2) 
is activated through protein kinase C, ROS are released and enzymes like the neutrophil elastase and 
MPO translocate into the nucleus to promote nuclear remodeling and NET release [155, 163]. 
Alternatively, neutrophil treatment with calcium ionophores such as A23187 triggers the NOX2-
independent activation of peptidyl arginine deiminase 4 (PAD4) leading to decondensation of the 
chromatin. The nuclear membrane disrupts. Now the chromatin is being released into the cytosol. Here 
the granule and cytosolic proteins decorate the chromatin. In the end, the plasma membrane ruptures, 
the nuclear DNA is released, NETs are formed and the neutrophils die [164].  
Vital NETosis, not depending on ROS 
It has been shown that vital NETosis may be induced within 5 to 60 minutes after contact with bacteria 
via toll like receptors. It is assumed that PAD4 is activated without any oxidants. The chromatin 
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decondensates. Neutrophil elastase translocates to the nucleus to further enhance chromatin unfolding 
and disruption of the nuclear membrane. During vital NETosis the neutrophil stays alive due to the fact 
that the chromatin is expelled in form of vesicles. The neutrophil is still able to function partly afterwards 
[164, 165].  
Vital NETosis, depending on ROS 
In 2009 Yousefi described a third form of NETosis [151]. Here neutrophils are able to release their 
mitochondrial DNA. It has been shown that this pathway is ROS dependent. When DPI is added, no 
mitochondrial NETosis is observed. This form of NETosis does not lead to cell death [151] and has been 
observed in patients with systemic lupus erythematosus [166]. Immune complexes activate neutrophils 
leading to mitochondrial ROS production. The mitochondria are extruded to the surface of the cells 
where they release their DNA. They can also be detected together with expelled nuclear NETs [166].  
2.11.3. NETosis in disease  
NET formation is not only observed in pathogen defense but is also associated with various diseases like 
systemic lupus erythematosus [167], chronic granulomatous disease [168] and vasculitis [169]. NETs are 
also able to recruit platelets and neutrophils to the endothelium, supporting the pathogenesis of venous 
thrombosis [170, 171]. 
As mentioned in section 2.11.1. NETosis plays an important role in the immune response [172]. About 
5% of the proteins in NETs is neutrophil elastase [146] which degrades virulence factors and pathogens 
[173]. On the other hand, bacteria expressing DNase are more pathogenic since they avoid being 
trapped by NETs [174]. It has been speculated that chronic bacterial infections sustain a basal NETosis 
activity in the body which may trigger AAA formation, e.g., NETs may contribute to AAA development 
in conjunction with periodontitis [144]. In this study it has been observed that markers for NETs, like 
citrullinated histones and cell-free DNA (cfDNA), are elevated in the luminal part of the ILT and the 
adventitia of the abdominal aortic aneurysm wall. In addition, in the plasma of AAA patients levels of 
cfDNA and DNA-myeloperoxidase complexes were increased in comparison to a healthy control group. 
NETs were also detected in the aortic aneurysm tissue. Likewise, in an animal model of AAA formation, 
plasma levels of cfDNA and DNA-MPO complexes were elevated [144].  
 
2.11.4. Inhibition of NETosis                                                        
 
In an experimental animal model for AAA the aorta of mice was perfused with elastase to trigger 
aneurysm formation and DNase1 was applied to destroy NETs [175]. It was found that AAA formation 
was decreased when DNase1 was administered on days 0-5 post elastase treatment, but DNase1 
injections on days 4-9 were not able to suppress AAA development. In the study it has been noted that 
the effect of delayed DNase1 application should be evaluated in an animal model that more closely 
mimics the pathogenesis of human aneurysm formation [175].  
Treatment with DNase1 enzymatically degrades DNA molecules of already formed NETs. Other 
treatments focus on the inhibition of early steps in NETosis to prevent NET formation. The 
transformation of arginine to citrulline residues is modulated through the enzymes protein arginine 
deiminases 1, 2, 3, 4 and 6 [176, 177]. Especially high levels of PAD4 have been detected in neutrophil 
granulocytes. For the activation of PAD4 calcium is needed [178]. PAD4 is able to citrullinate the arginine 
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of histones leading to a weakening of the electrostatic binding between histones and DNA [179]. It has 
been observed that PAD4 deficient mice are unable to form NETs [180].  
GSK484, a selective and reversible PAD4 inhibitor, has been developed [177]. The compound binds to 
the non-activated form of PAD4. GSK484 has a half maximal inhibitory concentration of 50 nM. In human 
and in murine neutrophils histone H3 citrullination and NET formation has been reduced through 














3.  Study Hypotheses and Aims 
Considering the importance of recruitment and activation of neutrophils for the development of AAA, 
the working hypothesis is raised that increased NETosis may accelerate the growth of AAA. To date, the 
therapeutic and marker potential of NETs in AAA has not been fully examined.  Therefore, the aims of 
this study are 
1. to analyze different parameters which reflect neutrophil activation and NETosis (DNA-histone 
complexes, MPO-histone complexes, MPO and citrullinated histone H3) in plasma of AAA patients being 
monitored in the pre- and post-surgery phase. Furthermore, the NETosis parameters are to be evaluated 
for their potential to predict disease progression. 
2. to test the therapeutic impact of anti-NET therapy in established disease with a recently developed, 
highly selective and reversible PAD4 inhibitor (GSK484) which inhibits histone citrullination by PAD4 and 
therefore reduces neutrophil extracellular trap formation in human and mouse neutrophils. This work 
aims to determine the optimal in vivo application and dosage of GSK484 in an experimental model of 
AAA based on ApoE deficient mice exposed to angiotensin II (AngII).  
Based on the proposed study, we expect to gain more scientific knowledge on the therapeutic and 






4. Materials and Methods 
4.1. Human Study 
4.1.1. Human Study Design 
The protocol was approved by the Ethics Committee of the Medical University of Vienna as part of the 
clinical study “Predictive Potential of Neutrophil and NET Biomarkers in Patients with Abdominal Aortic 
Aneurysm” (no. 1729/2014).  
All patients gave written, informed consent to participate in this clinical study. Patients diagnosed with 
an abdominal aortic aneurysm were recruited through the Vascular Surgery outpatient clinic of the 
Medical University of Vienna.   
Every six months visits were being scheduled to withdraw blood for biomarker analysis and to conduct 
a CTA scan in order to asses AAA growth. In case of surgical repair, blood was collected immediately 
prior to the intervention and at 3-6 months thereafter. 
Patients with following diseases were excluded:  
- Rare types of AAA with special genesis such as in Ehlers-Danlos syndrome and Marfan syndrome 
- Oncological disease: present carcinoma or chemotherapy during the last year 
- Hematological disorders 
- Organ transplantation or immunosuppression 
- Autoimmune diseases 
 
Patients did not suffer from any current or recent infection at the time of blood withdrawal. 
A total of 100 long-term follow-up patients were scheduled for a monitoring period of three years. In 
this thesis only a part of this collective was analyzed.  
4.1.2. Blood Sampling 
Per patient following samples were taken: one serum tube with a gel plug and one hirudinized tube 
(Roche, Basel, Switzerland) at room temperature and three CTAD plasma tubes at 4°C (Greiner Bio-One, 
Kremsmünster, Austria) containing a mixture of citrate, theophylline, adenosine and dipyridamole 
(CTAD).  
The total number of neutrophils was determined in hirudinized whole blood using a hemocytometer 
(Sysmex XN-350 Europe GmbH Europe, Norderstedt, Germany).  
4.1.2.1. Preparation of Plasma 
For the plasma preparation the CTAD tubes were kept on ice for at least 10 minutes before being 
centrifuged. Then the blood was centrifuged at 1000 x g (2500 rpm) at 4°C for 10 minutes using the 
Rotanta 460 RC centrifuge (Hettich, Kirchlengern, Germany). The supernatant was collected, briefly 
mixed with an IKA Vortex Genius 3 (IKA-Werke GmbH & Co. KG, Staufen, Germany) and again 
centrifuged at 10000 x g (10000 rpm) at 4°C for 10 minutes with the Microfuge 22R centrifuge (Beckman 
Coulter, Brea, California, USA). The samples were stored in aliquots at –80°C. 
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4.1.2.2. Routine Laboratory Blood Analysis 
In addition to the determination of NET markers in plasma by enzyme-linked immunosorbent assay 
(ELISA), a routine hospital laboratory analysis was conducted for each patient. This enabled to compare 
the explorative parameters to established blood markers of cardiovascular disease such as total 
cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, 
lipoprotein a, C-reactive protein (CRP), creatinine, urea, free hemoglobin, fibrinogen and D-dimer.  
 
4.1.3. Enzyme-Linked Immunosorbent Assay 
 
4.1.3.1. Cell Death Detection ELISA  
The Cell Death Detection ELISA (Roche, Mannheim, Germany, no. 11 544 675 001) measured complexes 
of DNA with histones (H1, H2, H3, H4) released upon cell death. The sandwich antibodies were directed 
against DNA and histones.  
Plate coating: The plate was coated one day before assay performance. The anti-histone solution was 
reconstituted by adding 1 ml sterile water. Then 1 ml of the 10 x coating buffer was diluted in 9 ml sterile 
water (1:10). The coating solution was prepared by mixing 1 ml anti-histone solution and 9.5 ml coating 
buffer. 100 µl coating solution were added to each well. The plate was incubated at 4oC for 19 hours at 
600 rpm (shaker IKA MS3 digital, IKA-Werke, Staufen, Germany). 
Plate blocking: The next day the plate was emptied and 200 µl incubation buffer were added. The plate 
was placed at room temperature (RT) for 30 minutes onto the shaker.  
Preparation of plasma samples and standards: In the meantime plasma samples from -80°C were 
thawed at RT. Afterwards they were mixed with the vortex and briefly centrifuged.  
The self-made standard stock was thawed. The stock was composed of culture supernatant from 
isolated human neutrophils, stimulated for 3 hours by PMA for NETosis induction and stored at -80°C. 
The standard was of unknown concentration of free DNA-histone complexes and could hence only be 
applied as a relative reference. The standard dilution series was prepared as follows: 1:9, 1:27, 1:81, 
1:243, 1:729 and blank, resulting in relative reference values of 81, 27, 9, 3, 1 and 0. 
Washing buffer was diluted (1:10) in deionized water. After blocking, the plate was washed three times; 
95 µl of standards were added into each well of the first row.  Then 95 µl of sample (CTAD plasma) were 
added to each well in duplicates. The plate was coved with an adhesive strip and incubated with 
agitation at RT for 1.5 hours.  
Addition of detection antibody: Anti-DNA solution was reconstituted by adding 1 ml of sterile water. 
Conjugate solution was prepared by mixing 1 ml anti-DNA solution with 9.5 ml incubation buffer. The 
plate was washed three times. Then, 100 µl conjugate solution were added to each well. The plate was 
covered with an adhesive strip and incubated/agitated at RT for 1.5 hours. Subsequently, the plate was 
washed three times.  
Addition of substrate: 3 ABTS tablets were dissolved in 15 ml substrate buffer; 100 µl of substrate were 
added to each well.  
Measurement: The plate was incubated for 10-20 min protected from light. Measurements were 
conducted after 10, 16, 23 minutes. The optical density was measured at 405 nm wavelength and 490 




4.1.3.2. Human Myeloperoxidase ELISA  
Preparation of MPO ELISA (R&D Systems, Minneapolis, Minnesota, USA, no. DMYE00B) components: 
Wash buffer was diluted (1:25) with deionized water. Standard was diluted by simply adding water (to 
a final concentration of 100 ng/ml after reconstitution). CTAD plasma samples from -80°C were thawed 
at RT and afterwards mixed with the Vortex instrument. 
Preparation of plasma samples and standards: Plasma samples were diluted with RD6-58 calibrator 
diluent (1:10). The standard was diluted with RD6-58 buffer to the following concentrations: 10.00 
ng/ml, 3.33 ng/ml, 1.11 ng/ml, 0.37 ng/ml, 0.12 ng/ml and blank.  
Distribution of plasma samples and standards: 100 µl of RD1-27 buffer were added to each well and 
50 µl of standard were distributed into the first row. 50 µl of diluted plasma samples of patients were 
added per well (in duplicates). The plate was covered with an adhesive strip and incubated at RT for 2 
hours at 500 rpm.  
Addition of detection antibody: The plate was washed 4 times with wash buffer. 200 µl MPO conjugate 
were added to each well. The plate was covered by adhesive strip and incubated at RT for 2 hours at 
500 rpm. 
Addition of substrate: The plate was washed 4 times with wash buffer. Equal volumes of color reagents 
A and B were mixed together in order to prepare the substrate solution. 200 µl of substrate solution 
were added to each well. The plate was incubated for 30 min without agitation and protected from light. 
The incubation time was 30 minutes.  
Measurement: 50 µl stop solution were added to each well. The content in each well was pipetted up 
and down 8-10 times until the color completely changed to yellow. Optical density was measured at 450 
nm and for correction, at 540 nm wavelength.  
 
4.1.3.3. Histone-CitH3 ELISA 
 
The histone-citH3 ELISA was partly based on the Cell Death Detection Kit (Roche, Basel, Switzerland, no. 
11 544 675 001) but modified to measure citrullinated histone H3 (citH3) released upon NETosis [181].  
 
Preparation of standard: 1 μg of recombinant human PAD4 (Cayman Chemicals, Ann Arbor, Michigan, 
USA) was mixed with 2 μg of recombinant human histone H3.1 (New England Biolabs, Ipswich, 
Massachusetts, USA) in a total of 20 μl of the following buffer: 50 mM Tris-HCl at pH 7.6, 4 mM CaCl2 
(calcium chloride), 1 mM phenylmethylsulfonyl fluoride and 4 mM dithiothreitol. The solution was 
incubated for 2 h at 37°C. The mix was diluted in phosphate-buffered saline deficient of Ca2+ und Mg2+ 
(PBS-/-) for a final concentration of 1 μg/ml of citrullinated histone H3 and stored at -20°C.  
Plate coating: Anti-histone solution was prepared by adding 1 ml sterile water. Coating buffer was 
diluted 1:10 with sterile water. Coating solution was prepared by mixing 1 ml anti-histone solution with 
9.5 ml coating buffer; 100 µl of coating solution was added to each well. The plate was covered by 
adhesive strip and incubated (generally under agitation) at 4oC overnight.  
Preparation of plasma samples and standards: Washing buffer was prepared by adding 0.05% Tween20 
in PBS-/-. 200 µl of incubation buffer was added to each well. The plate was covered with adhesive strip 
and incubated at RT for 1 h. Plasma samples from -80°C were thawed at RT and mixed. The prepared 
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standard was diluted with incubation buffer to following concentrations: 500 ng/ml, 166.7 ng/ml, 55.6 
ng/ml, 18.5 ng/ml 6.17 ng/ml and blank. 
Distribution of samples and standards: The plate was washed 3 times with wash buffer. Afterwards 50 
µl of standards were added into each well of the first row. 50 µl of patient plasma sample were added 
per well (in duplicates). The plate was covered with an adhesive strip and incubated at RT for 1.5 hours.  
In the meantime bovine serum albumin (BSA) was dissolved in PBS-/- (at a final concentration of 1% 
BSA; Sigma-Aldrich, St. Louis, Missouri, USA, no. A7030, stored at 4°C). Anti-citH3 antibody (Abcam, 
Cambridge, United Kingdom, no. ab5103) was diluted 1:1000 in PBS-BSA 1%. 
Addition of detection antibody: The plate was washed three times with washing buffer. 100 µl of anti-
citH3 antibody were added to each well. The plate was covered with an adhesive strip and kept at RT 
for 1.5 hours. 
In the meantime anti-rabbit horseradish peroxidase conjugate (Cell Signaling, Danvers, Massachusettes, 
USA, no. 7074S) was diluted 1:2000 in PBS-BSA 1%. 
Addition of conjugated secondary antibody: The plate was washed three times with washing buffer. 
100 µl of anti-rabbit horseradish peroxidase antibody was added to each well. The plate was covered 
by adhesive strip and incubated at RT for 1 hour.  
In the meantime stop solution, consisting of 2% sulfuric acid, was prepared.  
Addition of substrate: The plate was washed three times with washing buffer. 100 µl substrate were 
added to each well. The plate was incubated for 30 minutes protected from light. Afterwards 50 µl stop 
solution were added to each well. Optical density was measured at 450 nm and 540 nm wavelength, for 
correction. 
 
4.1.3.4. MPO-Histone ELISA 
A combination of the Cell Death Detection ELISA (Roche no. 11 544 675 001) and the myeloperoxidase 
ELISA (R&D Systems, Minneapolis, Minnesota, USA, no. DMYE00B) was applied to measure complexes 
of MPO with histones (H1, H2, H3, H4) released upon neutrophil cell death. The sandwich antibodies 
were directed against MPO and histones. 
Plate coating: Anti-histone solution was reconstituted by adding 1 ml sterile water. Coating buffer was 
diluted 1:10 with sterile water. Coating solution was prepared by mixing 1 ml anti-histone solution and 
9.5 ml coating buffer. 100 µl of coating solution were added to each well. The plate was covered by 
adhesive strip and incubated at 4oC overnight at 600 rpm (on the IKA MS3 digital plate shaker). 
Plate blocking: Washing buffer was diluted 1:10 with deionized water. 200 µl of incubation buffer were 
added to each well. The plate was covered with an adhesive strip and kept at RT for 30 min with 
agitation. In the meantime CTAD plasma samples were retrieved from -80oC, thawed at RT and vortexed.  
Preparation of plasma samples and standards: A self-made standard was prepared from supernatant 
of isolated human neutrophils, stimulated for 3 h by PMA for NETosis induction and stored at -80°C. The 
standard had an unknown concentration of free histone-MPO complexes and was hence applied as a 
relative reference. The standard was thawed and diluted with incubation buffer at 1:2, 1:6, 1:18, 1:54, 
1:162 and blank, resulting in relative reference values of 81, 27, 9, 3, 1 and 0. 
Distribution of plasma samples and standards: The plate was washed three times with washing buffer. 
Afterwards 95 µl of standard were added to the wells in the first row. 95 µl of sample were added to 
the rest of the wells in duplicates. The plate was covered by adhesive strip and incubated with agitation 
at RT for 1.5 hours. 
Subsequently, the ELISA procedure was switched to the MPO ELISA components. 
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Addition of detection antibody: MPO ELISA wash buffer was diluted 1:25 with deionized water. The 
plate was washed four times with washing buffer. 150 µl MPO conjugate were added to each well. The 
plate was covered with an adhesive strip and incubated at RT for 2 hours at 500 rpm. 
Addition of substrate: Equal volumes of color reagents A and B were mixed. The plate was washed four 
times with washing buffer. 150 µl of substrate were added to each well. The plate was incubated for 30 
minutes without agitation and protected from light.           
 Measurement: 50 µl stop solution were added to each well and pipetted up and down for 8-10 times 
until the color was completely changed to yellow. Optical density was measured using 450 nm and 540 







































4.2. Animal Study  
4.2.1.  Mouse Model of AAA Formation 
The study protocol “The Therapeutic Potential of Neutrophil Extracellular Traps (NETs) in Abdominal 
Aortic Aneurysms” was approved by the Ethic 
s Committee for Animal Experimentation of the Medical University of Vienna and by the Austrian 
Ministry of Science (GZ 66.009/0355-WF/V/3b/2016).  
 
There are a number of different AAA animal models, like the elastase perfused rat model, the elastase 
perfused mouse model and the angiotensin II infused mouse model. However, not all of them mimic 
the risk factors of the human disease and some do not even develop a thrombus [182-185]. For this 
study the angiotensin II infused mouse model was used due to the fact that it mimics several essential 
human risk factors. Mice homozygous for the ApoE mutation develop hyperlipidemia. The treatment 
with angiotensin II leads to hypertension. The mice are of male gender. All these risk factors in 
combination play an important part during the pathogenesis of AAA. It also has been observed that 
angiotensin II infusion leads to an increased infiltration of macrophages resulting in a dilatation of the 
wall [186, 187]. In addition, this model generates an atherosclerotic lesion, luminal dilatation, medial 
degeneration, inflammation and intramural thrombus development. However, it has to be noted that 
the aneurysm forms suprarenal and the thrombus develops  intramural, whereas in humans most 
aneurysm are located infrarenal and the thrombus forms in the luminal part of the aorta [188]. 
4.2.2. Animal Study Design 
B6.129P2-ApoEtm1Unc/J mice, homozygous for the ApoE mutation, were obtained from the 
Department of Biomedical Research at the Medical University of Vienna (Ass.-Prof. Dr. Harald Höger). 
All mice were fed a normal chow diet with fresh, clean water ad libitum. After pump implantation they 
were kept in individual cages. Mice were aged between 8-12 weeks and were of male gender for the 
experiment. The animals weight between 25-30 g.  
The first part of the study focused on determining an appropriate in vivo dosing of GSK484, due to the 
fact that until this time the PAD4 inhibitor, GSK484, had only been tested in vitro. Therefore, GSK484 
was injected into the vena jugularis externa at the following concentrations: 0.2 µg, 2 µg or 20 µg/g 
body weight. Mice were closely observed for toxicity or aberrant behavior within the next day. After 24 
hours the blood was harvested from the vena cava inferior. Neutrophils were isolated, blood smears 
were performed and DNA release was measured upon in vitro NET induction. 
The second part of the study was conducted after the appropriate in vivo dosage of GSK484 had been 
determined. Mice were implanted with an osmotic angiotensin II (Ang II) pump. After 14 days a catheter 
was inserted into the vena jugularis externa and mice were treated with GSK484 or PBS-/- for negative 
control daily via the intravenous port. At day 28 mice were sacrificed and blood samples were taken for 
NET detection. The maximum diameter of the suprarenal abdominal aorta was assessed by ultrasound 
at baseline, day 14 and day 28 to monitor AAA development. 
4.2.3. Injection into the Vena Jugularis Externa 
Mice were anesthetized with isoflurane at a flow rate of 1-2%. Buprenorphine (0.01 ml/g body weight) 
was injected subcutaneously in order to prevent pain sensation. Animals were kept on heating pads to 
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avoid hypothermia. Eyes were protected by an ocular gel. After hair removal, the skin was disinfected 
with betaisodona (povidone-iodine). The vena jugularis externa was prepared under the microscope 
(Leica, Wetzlar, Germany, M651). The distal part of the vena was ligated (Fig. 1).  
The GSK484 (PAD4 inhibitor) stock was dissolved in ethanol at 20 mg/ml. Afterwards GSK484 was diluted 
with PBS -/- in order to apply either 0.2, 2.0 or 20 µg per g mouse weight into the vena jugularis externa 
with a bent 30G needle.  
Then the proximal part of the vessel was immediately ligated. In the end mice were sutured. During the 
whole procedure the general condition of the animals was monitored by checking posture, breathing 
frequency and activity. 
Materials: suture (B. Braun, Maria Enzersdorf, Austria, Silkam 7/0, , no. 0766038), skin suture (Covidien, 
Dublin, Ireland,  Polysorb 4-0 CV-23,), 30 G needle (B.Braun, Sterican), GSK484 (Cayman ChemicalsAnn 
Arbor, Michigan, USA , no. 17488) stock solution of 20 mg/ml (39.22 mM) in ethanol, stored at -20°C 
A B C 
   
Figure 1: Injection into the vena jugularis externa.                                     
A) Preparation of the vena jugularis externa and preparation of the ligations B) Injection into vena jugularis externa C) Complete 
ligation of vena jugularis externa        
 
4.2.4. Blood Collection 
At first the animals were anesthetized with 100 mg/kg ketamine and 5 mg/kg xylazine. Afterwards the 
abdomen was opened via laparotomy. The vena cava inferior was prepared (Fig. 2). Before the blood 
was taken each syringe was coated with EDTA solution. On an average about 0.5-1 ml blood was drawn 
from each mouse. Then this blood sample was transferred into the mini EDTA blood collection tubes. 
Material needed per mouse: 2 × 1 ml syringe, 27¾ G needle (Microlance 3, Dublin, Ireland, no. 302200), 
9× EDTA solution in PBS-/- (EDTA contained in one 9 ml EDTA blood collection tube was dissolved in 1 
ml PBS-/-), 1 ml EDTA blood collection tubes (e.g. Greiner Bio-one, Kremsmünster, Austria, MiniCollect 






Figure 2: Blood withdrawal from vena cava inferior.                                                                                                       
A) Preparation of vena cava inferior, B) Blood withdrawal from vena cava inferior 
                                      
4.2.5. Isolation of Neutrophil Granulocytes  
The isolation was performed with the Easy Step Mouse Neutrophil Enrichment Kit (Stemcell 
Technologies, Vancouver, Canada, no. 19762A) based on negative selection, i.e. removal of non-
granulocytes from whole blood by antibody labeling and magnetic particles. All steps were performed 
on ice. To lyse erythrocytes 1 ml of EDTA-anticoagulated blood was mixed with 9 ml of precooled 
ammonium chloride solution. The suspension was mixed by gently inverting the tube a few times and 
was then incubated on ice for 15 minutes. The tube was centrifuged at 300 × g for 6 minutes at 4°C: The 
supernatant was discarded. The cell pellet was gently resuspended in recommended medium at 3 ml of 
medium per 1 ml of original blood.  
Then, 110 µl were used to count the white blood cells. First, 10 µl were mixed with 10 µl trypan blue 
solution and evaluated in the manual counting chamber. The remaining 100 µl were used to count the 
cells via Sysmex XN-350 device using the body fluid program.  
Thereafter, medium was added to the cells at 10 ml per 1 ml original blood volume. The suspension was 
again centrifuged at 300 × g for 6 minutes at 4°C. The supernatant was discarded.  The cell pellet was 
resuspended and diluted to obtain 1×108 cells/ml medium. Mostly, a yield of 50×106 cells in 500 µl 
medium was reached. The suspension was transferred into a 5 ml polystyrene round bottom tube.  
50 µl rat serum were added per ml of medium. Comparably, 50 µl enrichment cocktail were added to 
each ml of the sample. The cell suspension was gently mixed with a 1000 µl pipette and incubated for 
15 minutes on ice. Then medium was added to each sample (final volume 4.5 ml). The cells were 
centrifuged at 300 × g for 10 minutes at 4°C. Supernatant was discarded and the cell pellet was 






added per ml of sample. The suspension was gently mixed with a 1000 µl pipette and incubated for 15 
minutes on ice. 
Prior to adding 150 µl magnetic particles per sample, the particles were vortexed for 30 seconds. The 
cell suspension was supplied with the particles, gently mixed with a 1000 µl pipette and incubated for 
10 minutes on ice. The samples were topped up with medium to a final volume of 2.5 ml. The suspension 
was again mixed with a 1000 µl pipette. The polystyrene tubes were placed onto the magnet and 
incubated for 5 minutes at room temperature. The labelled cells (non-neutrophils) accumulated at the 
magnet. The rest of the suspension was pipetted into a new polystyrene tube. 
The neutrophils were counted manually and via Sysmex device in body fluid mode. For the manual count 
10 µl cell suspension and 10 µl trypan blue were mixed. Cell numbers were determined via counting 
chamber under the microscope (Zeiss, Oberkochen, Germany, Axiovert 40 CFL).  
In order to confirm that the isolated cells are actually neutrophils, 20 µl of cell suspension were 
incubated with 2 µl of Ly6G antibody directly conjugated to AlexaFluorA488 dye (BioLegend, San Diego, 
California, USA, no. 127626) for 10 minutes at room temperature. Then 480 μl PBS-/- were added. The 
neutrophil measurement was conducted by flow cytometry in a Gallios instrument (Beckman Coulter, 
Brea, California, USA). 
Materials: Easy Step Mouse Neutrophil Enrichment Kit (Stemcell Technologies, no.19762A), Easy Eights 
Magnet (Stemcell Technologies, no. 18103), polystyrene tubes, trypan blue solution (0.4%) (Life 
Technologies, no. 15250-061), normal rat serum (Stemcell Technologies, no. 13551), ammonium 
chloride solution stored at -20°C (Stemcell Technologies, no. 07850), 50 mM EDTA stock solution: 18.6 
mg EDTA dissolved in 1 ml PBS-/- and filtered at 0.22 µm, “recommended medium” was prepared and 
stored at +4°C: 500 ml PBS-/-, 10 ml fetal bovine serum (2%), 10 ml 50 mM EDTA stock for a final 
concentration of 1 mM EDTA 
 
4.2.6. DNA Release Assay  
First, a predilution of A23187 in Hank´s balanced salt solution with calcium and magnesium (HBSS+/+) 
was prepared at a ratio of 1:100 to reach a final concentration of 200 µM.  If necessary, this solution 
was further diluted 1:2 to reach 100, 50, 25 µM and 12.5 µM of A23187. Second, 5 mM SYTOX Green 
was added to HBSS+/+ at a 1:100 ratio to achieve 50 µM. Third, predilutions of GSK484 were conducted 
using the 20 mM stock in HBSS+/+: 20 µl GSK484 stock were added to 80 µl HBSS+/+ (1:5 dilution to 4 
mM). Then, 20 µl thereof were combined with 80 µl HBSS+/+ (additional 1:5 dilution to 800 µM). Fourth, 
comparable predilutions were generated from the 40 mM GSK484 stock dissolved in ethanol:  10 µl 40 
mM GSK484 stock were added to 90 µl HBSS+/+ (4 mM) and 20 µl  thereof were combined with 80 µl 
HBSS+/+ (800 µM). 
After the mouse neutrophils had been isolated with the Easy Step Mouse Neutrophil Enrichment Kit, in 
most experiments they were pooled from all mice due to a low yield of cells. Afterwards the neutrophils 
were brought to a concentration of 1×106/ml in HBSS+/+. The required amount of all components for 
the DNA release assay (performed in a 96-well plate) was calculated as listed in Table 1, resulting in 
50000 neutrophils/well and a final volume of 150 µl per well. First, HBSS+/+ was pipetted into the wells. 
The indicated concentrations of GSK484 were added to the required wells. Then, 50 µl of cells (50000 
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neutrophils) were added per well, followed by incubation at 37°C for 30 minutes in the Heraeus 
incubator (Thermo Fisher Scientific, Waltham, Massachusetts,USA) in order to inhibit PAD4 activity. 
Afterwards the indicated volume of A23187 was added to the required wells to trigger NET formation. 
Finally, SYTOX Green (prediluted) was added to all wells to fluorescently label cell-free DNA released 
upon NETosis. The fluorescence measurement was conducted with the Varioskan Flash plate reader 
(Thermo Fisher Scientific).  
Materials:  HBSS+/+ (Lonza, Basel, Switzerland, no. BE10-527F), A23187 calcium ionophore (Sigma 
Aldrich, no. C7522) 20 mM stock in dimethyl sulfoxide, GSK484 (Cayman Chemicals, no. 17488) 20 mM 
stock in in HBSS+/+ and 40 mM stock in ethanol stored at -20°C, SYTOX Green (Thermo Fisher 
Scientific, no. S7020) supplied as 5 mM stock in dimethyl sulfoxide and stored at -20°C, black 96-well 






















85 50 - - 15 - 
Untreated  
+ EtOH 
77.5 50 - - 15 7.5 
A23187 133 µM 
 
84 50 - 1 (20 mM) 15 - 
A23187 4 µM 82 50 - 3 (200 µM) 15 
 
- 
A23187 4 µM  
+ EtOH 
74.5 50 - 3 (200 µM) 15 7.5 
 
A23187 2 µM  
+ EtOH 
74.5 50 - 3 (100 µM) 15 7.5 
A23187 1 µM  
+ EtOH 
74.5 50 - 3 (50 µM) 15 7.5 
A23187 0.5 µM  
+ EtOH 
74.5 50 - 3 (25 µM) 15 7.5 
A23187 0.25 µM  
+ EtOH 
74.5 50 - 3 (12.5 µM) 15 7.5 
GSK484 2 mM HBSS++ 70 50 15 (20 mM) 
HBSS++ 
- 15 - 
GSK484 80 µM HBSS++ 70 50 15 (800 µM) 
HBSS++ 
- 15 - 
GSK484 2 mM EtOH 77.5 50 7.5 (40 mM) 
EtOH 
- 15 - 
GSK484 80 µM EtOH 70 50 15 (800 µM) 
EtOH 
- 15 - 
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A23187 4 µM  
+ GSK484 2 mM HBSS++ 
67 50 15 (20 mM) 
HBSS++ 
3 (200 µM) 15 - 
A23187 4 µM  
+ GSK484 80 µM HBSS++ 
67 50 15 (800 µM) 
HBSS++ 
3 (200 µM) 15 - 
A23187 4 µM  
+ GSK484 2 mM EtOH 
74.5 50 7.5 (40 mM) 
EtOH 
3 (200 µM) 15 - 
A23187 4 µM  
+ GSK484 80 µM EtOH 
67 50 15 (800 µM) 
EtOH 
3 (200 µM) 15 - 
A23187 2 µM  
+ GSK484 2 mM EtOH 
74.5 50 7.5 (40 mM) 
EtOH 
3 (100 µM) 15 - 
 
Table 1: Pipetting scheme for the DNA release assay.                     
Abbreviations. EtOH, ethanol. neutros, neutrophil granulocytes. HBSS++, hanks balanced salt solution with calcium and 
magnesium.  
 
4.2.7. Ultrasound Analysis of Aneurysm Diameter 
 
Ultrasound imaging was performed with a high-frequency ultrasound device (Vevo 2100, VisualSonics, 
Toronto, Canada). The linear array probe had a peak of 55 MHz. The whole procedure was performed 
under general anesthesia with isoflurane at a flow rate of 1-2%. Animals were fixed onto heating pads 
in a dorsal position, as illustrated in Figure 3. The abdominal skin was shaved. Eyes were protected by 
an ocular gel. 
The baseline ultrasound was performed on the day of the implantation of the osmotic pumps for AngII 
administration. The follow-up ultrasound analyses were conducted on day 14 and 28 after the pump 
implantation. The abdominal aorta was measured from the outer vessel wall to the outer part of the 
opposite wall during systole in B-mode. 
At first the diameter and the area of the aorta was measured in short axis view at the following locations: 
infrarenal region, at the level of the left and right renal artery, at the level of the renal vein and twice in 
the suprarenal region. A mean area and aortic diameter was calculated for the suprarenal region. 
The diameter of the abdominal aorta was then measured in long axis view. The infrarenal aorta (from 
the iliac bifurcation to the arteria renalis) was measured at 4 different locations. The suprarenal region 




Figure 3: Ultrasound setting for short axis view of the abdominal aorta.                                                        
Mice were fixed in a dorsal position. Hair was removed from the abdominal skin.  
 
4.2.8. Osmotic Pump Implantation 
One day prior to the implantation the pumps were prepared (Fig. 4) [188]. First, the mice were weighed 
and the required amount of angiotensin II was calculated to be released at 1000 ng/kg/min over a time 
frame of 28 days. For example, for a mouse weighing 29 g the pump should dispense 29 ng AngII/min 
or 1740 ng/h. Since the osmotic pump releases 0.25 µl solution per hour, 168 µl are required for a total 
of 28 days with a loading concentration of 6960 ng/µl or 6.96 mg/ml. Therefore 2.08 mg Ang II were 
dissolved in 300 µl sterile saline and 250 µl of the solution were filled into the pump for a mouse 
weighing 29 g. The pump was closed with the flow moderator. Finally, the pumps were put into a 15 ml 
tube filled with saline for preconditioning overnight at room temperature 
     
Figure 4: ALZET Mini-Osmotic Pump Model 2004.                            
Image by DURECT Corporation (Cupertino, California, USA)[189] 
 
The next day the osmotic pumps were implanted into mice under general anesthesia with isoflurane at 
a flow rate of 1-2% (Fig. 5). Animals were kept on heating pads during the whole procedure in order to 
avoid hypothermia. Eyes were protected by an ocular gel. After disinfection a small cut was made on 
the back of the mouse. A subcutaneous pocket was prepared. Then the pump was inserted into the 
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mouse. Finally, the skin was sutured. The pumps remained for 28 days until sacrifice. Due to the 
semipermeable outer membrane interstitial fluid was entering the outer pump reservoir, gradually 
compressing the inner (impermeable) reservoir to slowly release Ang II into the mouse skin. 
Materials:  
ALZET Mini-Osmotic Pump, model 2004 (DURECT Corporation, Cupertino, California, USA), sutures 
(Covidien, Dublin, Ireland, Polysorb 4-0 CV-23,), angiotensin II (Bachem AG, Bubendorf, Switzerland, no. 
4006473.0025), physiological saline (sodium chloride solution) (Fresenius Kabi, Bad Homburg von der 
Höhe, Germany, no. 19KB03GB)                        
 
 
Figure 5: Implantation of the angiotensin II osmotic pump. 
 
4.2.9. Intravenous Mouse Port Implantation 
On day 14 of AngII treatment the port (Fig. 6) was implanted under general anesthesia, again using 
isoflurane at a flow rate of 1-2%. Animals were kept on heating pads during the whole procedure in 
order to avoid hypothermia. Eyes were protected by an ocular gel. Buprenorphine was injected at 0.01 
ml/g body weight subcutaneously in order to avoid pain sensation. After hair removal the skin was 
disinfected with betaisodona (povidone-iodine).  
The first incision was made ventrally and the vena jugularis externa was prepared. The distal part of the 
vein was ligated completely. The ligation of the proximal part of the vein was prepared. Before 










Figure 6: Mouse port system. 
A) Mouse port MMP-1S and 30cm 1.2Fr catheter B) Injection of saline into the port chamber for preparation 
 
After hair removal and disinfection with betaisodona a subcutaneous pocket was prepared. The port 
was implanted subcutaneously (Fig. 7 and 8). The port chamber was fixed to the skin with sutures in 
order to avoid any unwanted movement. With a pair of scissors a subcutaneous tunnel was prepared 
to connect the dorsal with the ventral incision (Fig. 9). 
 
                       
Figure 7: Dorsal subcutaneous implantation of the port. 
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Figure 8: Fixation of the port. 
                                                                
Figure 9: Preparing for implanting the catheter into the vena jugularis externa. 
 
The catheter was pulled from the dorsal side of the tunnel to the ventral side. The mouse was turned 
around. Then the catheter could be implanted into the vena jugularis externa. A small incision was made 
in the vein with a 27G needle. The catheter was carefully placed into the vein under constant rinsing 
with saline. Once the catheter was correctly placed the proximal part of the vein was ligated in order to 
fix the catheter (Fig. 10). 100 µl of PBS-/- were injected into the port chamber to check if the catheter 
was functioning. 
 
                                               
Figure 10: Fixation of the catheter in vena jugularis externa. 
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Due to the silicon nature of the port chamber, the mouse port is suited for serial intravenous injections 
(up to 100) without leakage from the chamber. The GSK484 treated mice received of 2.0 µg GSK484 in 
200 µl PBS-/- per g body weight once a day under anesthesia using isoflurane at a flow rate of 6% for 
about 30 seconds. For control, 200 µl of PBS-/- were injected into the port once a day under the same 
conditions (Fig. 11). 
                                      
Figure 11: Injection into the port chamber. 
Materials: Sutures (Covidien, Polysorb 4-0 CV-23), 7-0 Sikam silk, braided, coated, non-absorbable DMP7 
(Braun Surgical, no. 0766038), UNO Mouse Port (UNO B.V., Zevenaar, Netherlands, no. MMP-1S-30CM), 
Posi-Grip Huber point needle (UNO B.V.) 
 
4.2.10. NET Detection in Blood Smears  
At first a protocol for NET detection in blood smears from healthy human blood was implemented. 
Therefore, the already established immunostaining protocol for neutrophil extracellular traps and citH3 
was adapted [190]. After the blood - mixed with EDTA for anticoagulation purposes - was withdrawn it 
was incubated with A23187 at a final concentration of 10 or 50 µM for two hours at 37°C in order to 
induce NETosis. To this end, the 20 mM stock solution of A23187 in DMSO had to be prediluted to 250 
µM (1 µl A23187 stock + 79 µl PBS-/-) and 1.25 mM (5 µl A23187 stock + 75 µl PBS-/-), respectively and 
1 µl of the dilutions was added to 25 µl of whole blood. At the same time control samples were treated 
with DMSO dilutions, as a solvent control. After incubation in reaction tubes, the 25 µl blood were 
pipetted on an object slide and immediately spread by carefully moving the slide. After the smear had 
fully dried it was stored at -80°C.  
When ready to perform staining, object slides were transferred into a humid chamber. All procedures 
were performed at room temperature.  
The blood smear was fixed with 4% paraformaldehyde for 30 minutes. Afterwards the sample was 
washed with PBS -/- (pH 7.4) three times. Then the permeabilization buffer (0.2% Tween-PBS) was 
added onto the object slide for 15 min at RT. Thereafter, the slide was washed with PBS for three times. 
The smears were incubated with blocking buffer (containing 1.5% bovine serum albumin, 0.1% sodium 
azide in PBS) for one hour. The sample was washed with PBS three times. The primary rabbit antibody 
against citrullinated histone H4 (citH4) was diluted 1:1000 in the blocking buffer. 300 µl of this solution 
were pipetted onto the slide. The slide was incubated for one hour at 37°C. Then the sample was washed 
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with PBS-/- three times. The secondary anti-rabbit IgG antibody with AlexaFluor555 conjugate, the 
Hoechst 33342 stain and Ly6G-AlexaFluor488 conjugate were diluted 1:1000 in the blocking buffer. 
Again, 300 µl of this solution were pipetted onto the slide.  The slide was incubated for one hour at 37°C. 
In the end the coverslip was washed twice with PBS-/-, was carefully dried and mounted with a drop of 
Fluoromount-G reagent on the object slide. Slides were stored at 4°C until microscopy. 
Five pictures were taken randomly per slide with the LSM 700 confocal microscope (Zeiss) and objective 
20x / 0.8 Plan-Apochromat. Pictures were taken of blue (Hoechst), green (Ly6G) and red (citH4) 
fluorescent signals. 
Hoechst positive nuclei were counted in the defined region (frame size 173.68 µm x 173.68 µm). In a 
second step neutrophils were identified by Ly6G staining (green fluorescence). In addition, NETs were 
identified by the occurrence of Hoechst positive fragmented nuclei (early stages of NETosis) or DNA 
strings (late stages of NETosis). To confirm that the Hoechst positive strings or fragmented cells were 
NETs, citH4 antibody (red fluorescence) was used.  
The percentage of NETs in relation to white blood cells and neutrophils was determined.  
Counting protocol:  
- total cells: all Hoechst positive nuclei                    
- neutrophils: Hoechst positive nuclei and Ly6G antibody positive    
- NETs: Hoechst positive cells, also positive for Ly6G and citH4 antibody; additionally, Ly6G 
antibody positive string- like structures 
 
Materials: Object slides (LaborChemie GmbH, Vienna, Austria, Star Frost 76×26mm, no. E5501-CW), 
Fluoromount-G (Southern Biotech, Birmingham, Alabama, USA, no. 0100-01), cover slips (Thermo Fisher 
Scientific, Waltham, Massachusetts, USA, Menzel-Gläser 24×50mm), blocking buffer  with 1.5% bovine 
serum albumin (Sigma-Aldrich, St.Louis, Missouri, USA, no. A7030-50G) and 0.1% sodium azide in PBS-
/-), permeabilization buffer with 0.2% Tween20 (Sigma-Aldrich, no. 9005-64-5) in PBS-/- 
DNA dye: Hoechst 33342 trihydrochloride, trihydrate (Thermo Fisher Scientific, no. H3570)  
Antibodies:                        
Primary: anti-histone H4 (citrulline 4) antibody (Merck & Co., Kenilworth, New Jersey, USA, no.07-596) 
and AlexaFluor488 conjugated anti-mouse Ly6G (BioLegend, San Diego, California, USA, no. 127626) 








4.3. Statistical Analysis 
 
Statistical analysis was carried out with SPSS 23.0 Software (SPSS Inc., Chicago, IL, USA) and was based 
on non-parametric tests, since a study collective of only 5 pre and post-operative patients, 7 monitoring 
patients, 5 control mice and 5 GSK484 treated mice rarely follows normal distribution. This study was 
defined as an explorative study. Therefore, no corrections/adjustments for multiple testing were 
conducted.  
During the course of this evaluation several NETosis and routine laboratory parameters were analyzed. 
The Wilcoxon signed-rank test was applied to evaluate differences between the pre- and post-operative 
data as well as changes from monitoring time point one to time point two. The Mann Whitney U test 
was used to analyze the difference between AAA area/diameter progression and the percentage of NETs 
in blood smears of control mice and GSK484 treated mice. The results were displayed by boxplots. 
Furthermore, the correlation between parameters was assessed by Spearman´s coefficient in order to 
investigate a possible association with NETosis (NET parameters). The data are visualized by 
scattergrams. 
Data of DNA release assays were analyzed with the 2013 version of Microsoft Excel. 






5.1. Patient Study 
5.1.1. Pre- and Post-Surgery Analysis 
5.1.1.1. Patient Demographics 
The baseline characteristics of the patients are presented in Table 2. All of the 7 investigated AAA 
patients were men, which reflects the elevated risk of AAA development for male gender. This group 
showed an age range from 67 to 81 with a median of 71 years. The body mass index (BMI) ranged from 
22.4-28.4 with a median of 24.5. All patients had a positive smoking status. The pack years varied from 
5 to 60 (median of 30). Six men had smoked in their past and 1 person was a current smoker. As a likely 
result 42.9% suffered from chronic obstructive pulmonary disease. 
Concerning comorbidities associated with cardiovascular disease, 85.7% patients suffered from 
hypertension, 100% from hyperlipidemia, 28.6% from diabetes mellitus type II and 28.6% of the patients 
had experienced coronary artery disease and myocardial infarction.  
57.1% of patients underwent endovascular aneurysm repair and 42.9% underwent open surgical repair. 
The mean interval between blood withdrawal before and after surgery was 12 months (range: 6 – 16 
months). Within this collective there were no inflammatory or mycotic aneurysms.  
Parameter N (%) Median Min-Max 
Age (years) 7  71 67-81 
Body Mass Index 7  24.5 22.4-28.4 
Pack years 7  30 5-60 
Gender (male) 7 100   
Smoker Status     
Never 0 0   
Current 1 14.3   
Past 6 85.7   
Hypertension  6 85.7   
Hyperlipidemia 7 100   
Coronary artery 
disease 
2 28.6   
Myocardial 
infarction  
2 28.6   
Diabetes mellitus  2 28.6   
COPD  3 42.9   
Atherosclerotic 
aneurysm 
7 100   
Type of surgery     
EVAR 4 57.1   
OSR 3 42.9   
Table 2: Demographics of patients analyzed before and after surgery.            





                                                            5.1.1.2. Explorative Parameters 
 
As described in the methods, DNA-histone complexes, citrullinated histone 3 protein (citH3), 
myeloperoxidase protein and MPO-histone complexes were measured in plasma samples by ELISA. The 
data obtained were converted to ng/ml plasma or relative units (RU), as shown in Table 3.  
DNA-histone complexes, citH3 protein and MPO protein were significantly increased in AAA patients 
before surgery when compared to data obtained from plasma samples in the post-surgery phase. There 
was no significant difference in the plasma concentrations of MPO-histone complexes between the two 
time points of investigation.  
Parameter preOP postop p-value N 
 Median (min-max) Median (min-max)   
DNA–histone (RU) 34.62 (26.91-84.02) 16.66 (8.88-29.83) 0.018 7 
CitH3 (ng/ml) 281.45 (174.91-406.41) 200.58 (75.27-272.86) 0.043 7 
MPO-histone (RU) 7.77 (5.39-19.96) 10.02 (6.94-19.60) 0.612 7 
MPO (ng/ml) 21.31 (8.72-52.60) 13.81 (6.72-24.64) 0.028 7 
Table 3: Explorative parameters in AAA patients before (preOP) and after surgery (postOP).                                 
Abbreviations: RU, relative units. citH3, citrullinated histone 3. MPO, myeloperoxidase. 
In AAA patients DNA-histone complexes were significantly higher (p=0.018) before surgery when 
compared to the postoperative time point of investigation (Fig. 12A). Accordingly, the median of the 
preoperative samples was 34.62 RU (range: 26.91 - 84.02 RU) and in the postoperative samples less 
than half with 16.66 RU (range: 8.88 - 29.83 RU) (Table 3).  
In contrast to DNA histone complexes, MPO-histone complexes remained unchanged (Fig. 12B), i.e., the 
median of the preoperative samples was 7.77 RU (range 5.39 - 19.96 RU) and 10.02 RU (range: 6.94 - 
19.60 RU) after surgery (Table 3). 
The plasma concentration of MPO protein was elevated in the AAA patients before surgery and dropped 
significantly (p=0.028) after the surgical intervention (Fig. 12C); the median of the preoperative 
measurements was 21.31 ng/ml (range: 8.72 -52.60 ng/ml) and decreased to 13.81 ng/ml (range: 6.72 
- 24.64 ng/ml) after aneurysm repair (Table 3).  
The concentration of citH3 protein was found to be significantly higher (p=0.043) at the preoperative 
compared to the postoperative time point (Fig. 12D) with a median of 281.45 ng/ml (range: 174.91 - 
406.41 ng/ml) before surgery and of 200.58 ng/ml (range: 75.27 -272.86 ng/ml) after the intervention 













Figure 12: Explorative parameters in plasma of AAA patients before (preOP) and after (postOP) 
surgery.                      
Boxplots illustrate the different concentrations of A) RU of DNA-histone complexes B) RU of MPO-histone complexes C) MPO 
protein (ng/ml) and D) citH3 protein (ng/ml) in plasma of AAA patients before and after surgical aneurysm repair. Data are 
shown as boxplots with whiskers at minimum and maximum, box at 25th percentile and 75th percentile and a line at the 50th 
percentile. Outliers and extreme values are indicated by circles and asterisks, respectively.                                                  
Abbreviations. RU, relative unites. MPO, myeloperoxidase. citH3, citrullinated histone 3.  
                                              5.1.1.3. Laboratory parameters  
Common laboratory parameters were determined in AAA patients in order to characterize potential co-
morbidities. When comparing pre- and postoperative levels there were no significant differences with 
regard to mean thrombocyte volume, alpha amylase, 24-hydroxyvitamin D, C-reactive protein, low 
density lipoprotein, high density lipoprotein, total cholesterol, cholesterol/high density lipoprotein 
ratio, triglycerides, albumin, urea, creatinine, fibrinogen, activated partial thromboplastin time, 
monocytes, neutrophils, leukocytes and platelets (Table 4).  
           p=0.018 
                   p=0.028 
             p=0.043 
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On the other hand, concentrations of lipoprotein (a) (p=0.034) (Fig. 13A) and free hemoglobin (p=0.028) 
(Fig. 13 B) were elevated significantly in the preoperative blood analyses; the preoperative blood 
lipoprotein (a) levels displayed a median of 13.0 nmol/l (range: 9.0 - 303.0 nmol/l) as opposed to 11.0 
nmol/l (range: 7.0 - 254.0 nmol/l) after the surgical intervention. Free hemoglobin showed a median of 
3.70 mg/dl (range: 2.48 - 6.31 mg/dl) in the preoperative samples while in postoperative measurements 
the median had dropped to 2.22 mg/dl (range: 1.10 - 4.13 mg/dl) (Table 4). 
Also the percentage of lymphocytes was significantly higher (p=0.028) in the preoperative samples (Fig. 
13C) with a median of 31.5 (range: 18.3 - 40.4) before surgery and 24.1 (range: 12.0 - 31.8) after the 
intervention. In contrast to lymphocytes, the number of erythrocytes was significantly lower (p=0.018) 
in the pre-surgery phase (Fig. 13D) with a median of 4.68 x 106/µl (range: 4.43 - 5.39 x 106/µl) versus a 





    
Figure 13: Parameters determined by routine laboratory blood analysis in AAA patients pre 
(preOP) and post-surgery (postOP).          
The boxplots illustrate the distribution of A) lipoprotein (a) levels, B) free hemoglobin levels, C) the percentage of 
lymphocytes and D) number of erythrocytes in pre and postoperative blood samples of aneurysm patients. 
                  p=0.028 
              p=0.034 
              p=0.028 







preOP postOP p-value N 
 Median (min-max) Median (min-max)   
Lipoprotein (a) (nmol/l) 13.0 (9.0-303.0) 11.0 (7.0-254.0) 0.034 7 
Free hemoglobin (mg/dl) 3.70 (2.48-6.31) 2.22 (1.10-4.13) 0.028 7 
Lymphocytes (%) 31.5 (18.3-40.4) 24.1 ( 12.0-31.8) 0.028 7 
Erythrocytes  (106/µl) 4.68 (4.43-5.38) 4.92 (4.62-5.77) 0.018 7 
Platelets (103/µl) 170.0 (71.0-252.0) 215.0 (142.0-287.0) 0.091 7 
Leukocytes (10^3/µl) 6.2 (4.1-9.9) 6.0 (4.3-11.8) 0.735 7 
Monocytes (%) 11.2 (6.4-13.6) 9.5 (6.1-13.9) 0.463 7 
Neutrophils (%) 57.85 (53.00-69.20) 65.30 (56.30-76.90) 0.172 7 
Mean thrombocyte volume 10.3 (8.5-11.3) 10.5 (8.8-11.4) 0.497 7 
Activated partial          
thromboplastin time (s) 
37.8 (30.5-45.0) 36.8 (32.1-39.2) 0.237 7 
Fibrinogen (mg/dl) 279.0 (248.0-560.0) 336.0 (248.0-519.0) 0.917 7 
D-dimer (µg/ml) 1.095 (0.390-2.950) 1.420 (0.680-3.220) 0.753 7 
Albumin (g/l) 44.7 (39.7-47.5) 44.1 (43.0-48.2) 1.000 7 
C-reactive protein (mg/dl) 0.16 (0.03-1.12) 0.18 (0.03-1.83) 0.400 7 
Cholesterol total (mg/dl) 152.0 (110.0-197.0) 159.0 (108.0-194.0) 0.735 7 
Low density lipoprotein (mg/dl) 74.8 (32.2-117.4) 55.6 (40.2-138.4) 0.499 7 
Cholesterol/High density 
lipoprotein ratio 
3.5 (2.4-4.3) 3.0 (2.4-5.0) 0.753 7 
High density lipoprotein (mg/dl) 43.0 (36.0-61.0) 45.0 (35.0-62.0) 0.865 7 
Triglycerides (mg/dl) 99.0 (63.0-399.0) 120.0 (77.0-237.0) 0.735 7 
Urea (mg/dl) 20.8 (15.5-24.9) 24.7 (16.2-28.4) 0.091 7 
Creatinine (mg/dl) 1.00 (0.82-1.74) 1.29 (0.79-1.61) 1.000 7 
Alpha amylase (u/l) 91.0 (43.0-146.0) 106.0 (63.0-134.0) 0.735 7 
25-Hydroxyvitamin D (nmol/l) 42.1 (13.9-90.1) 76.0 (22.5-89.1) 0.176 7 
Table 4: Routine laboratory parameters in AAA patients before (preOP) and after surgery (postOP).  
 
                                              5.1.1.4. Correlation of parameters  
The pre- and postoperative data sets of the explorative and routine laboratory parameters were 
investigated for positive or negative correlations.    
Plasma levels of DNA-histone complexes, MPO and citH3 concentrations correlated positively and 
significantly (Table 5). To be specific, the most notable positive and significant correlations were 
obtained between DNA-histone complexes and citH3 protein (R=0.732, p=0.003) (Fig. 14A), DNA-
histone complexes and MPO protein (R=0.626, p=0.017) (Fig. 14B), as well as between citH3 protein and 







Parameter 1 Parameter 2 Rho p-value N 
DNA–histone (RU) CitH3 (ng/ml) 0.732 0.003 14 
DNA–histone (RU) MPO (ng/ml) 0.626 0.017 14 
CitH3 (ng/ml) MPO (ng/ml) 0.868 <0.001 14 
 Table 5: Correlation of explorative parameters in AAA patients.                  








Figure 14: Correlations of explorative parameters in AAA patients.  
The scatter grams illustrate the correlation of A) DNA-histone complexes and citH3 protein, B) DNA-histone complexes and 
MPO protein and C) MPO protein and citH3 protein in pre- and post-surgery plasma samples of AAA patients.                




As outlined in section 4.1.2.2., the analysis of common laboratory parameters, used to evaluate AAA 
patient comorbidities, showed that lipoprotein (a) and free hemoglobin blood levels were significantly 
higher pre than post-surgical aneurysm repair. It was tested whether lipoprotein (a) or free hemoglobin 
correlate with the explorative parameters, determined in this study (Table 6).   In fact, a positive and 
significant correlation was found between lipoprotein (a) and MPO protein (R=0.572, p=0.032) (Fig. 15A) 
and a trend between the percentage of lymphocytes and DNA-histone complexes (R=0.521, p=0.056) 
(Fig. 15B). There were no correlations between lipoprotein (a) blood concentration, level of free 
hemoglobin, percentage of lymphocytes or number of erythrocytes per µl blood with other explorative 
parameters (Table 6). 
A B 
  
Figure 14: Correlations of explorative and routine laboratory parameters in AAA patients.                        
The scatter diagrams illustrate the correlation of A) MPO protein and lipoprotein (a), B) DNA-histone complexes and 
percentage of lymphocytes in blood of AAA patients collected before and after surgical repair.                                                 
Abbreviations. MPO, myeloperoxidase. RU, relative units. 
 
Parameter 1 Parameter 2 Rho p-value N 
DNA–histone (RU) Lipoprotein (a) (nmol/l) -0.027 0.928 14 
DNA–histone (RU) Free hemoglobin (mg/dl) 0.030 0.296 14 
DNA–histone (RU) Lymphocytes (%) 0.521 0.056 14 
DNA–histone (RU) Erythrocytes  (106/µl) -0.323 0.260 14 
CitH3 (ng/ml) Lipoprotein (a) (nmol/l) -0.387 0.172 14 
CitH3 (ng/ml) Free hemoglobin (mg/dl) 0.301 0.296 14 
CitH3 (ng/ml) Lymphocytes (%) 0.196 0.503 14 
CitH3 (ng/ml) Erythrocytes  (106/µl) -0.248 0.392 14 
MPO (ng/ml) Lipoprotein (a) (nmol/l) -0.572 0.032 14 
MPO (ng/ml) Free hemoglobin (mg/dl) 0.051 0.864 14 
MPO (ng/ml) Lymphocytes (%) 0.099 0.737 14 
MPO (ng/ml) Erythrocytes  (10^6/µl) 0.095 0.748 14 
Table 6: Correlation of explorative and routine laboratory parameters which differed significantly in 
AAA patients pre/post surgery.                                   
Abbreviations. MPO, myeloperoxidase. citH3, citrullinated histone 3. RU, relative unites. 
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                        5.1.2. Monitoring Analysis 
                                             5.1.2.1. Patient Demographics  
The baseline characteristics of 5 AAA patients who were monitored with serial blood analyses are 
presented in Table 7.  
All AAA patients in this study were men which reflects their elevated risk for this disease (see section 
2.3. The age within this group ranged from 66 to 85 with a median at 73 years. The body mass index 
varied between 27.73 and 37.04 with a median of 30.93. Eighty % of the patients had a positive smoking 
status. The pack years showed a wide range from 0 to 50 with a median at 20. Forty % had smoked in 
their past and 40% were current smokers. Twenty % suffered from chronic obstructive pulmonary 
disease. Concerning comorbidities associated with cardiovascular disease, 60% of the patients suffered 
from hypertension, 60% from hyperlipidemia, 60% from coronary artery disease, 20 % from diabetes, 
and 60% had experienced myocardial infarction or stroke. 
Parameter N (%) Median Min-Max 
Age (years) 5  72.86 65.72-84.88 
Body Mass Index 5  30.93 27.73-37.04 
Pack years 5  20 0-50 
Time between blood 
analyses (months) 
9  6.0 5.1-9.1 
Time between CT 
analyses (months) 
9  6.0 4.5-10.2 
AAA progression     
slow 5 56   
fast 4 44   
Gender (male) 5 100   
Smoker Status     
never 1 20   
current 2 40   
past 2 40   
Hypertension 3 60   
Hyperlipidemia  3 60   
Coronary artery disease  3 60   
Myocardial infarction  2 40   
Stroke  1 20   
Diabetes mellitus 1 20   
COPD 1 20   
 Table 7: Demographics of AAA patients included in monitoring analysis.                               
Abbreviations: COPD, chronic obstructive pulmonary disease. CT, computer tomography. AAA, abdominal aortic aneurysm.  
 
                                                5.1.2.2. Explorative Parameters 
As described in the methods 4.1.3.1. - 4.1.3.4., DNA-histone complexes, citrullinated histone 3 protein, 
myeloperoxidase protein and MPO-histone complexes were measured by ELISA, as seen in Table 8. The 
maximum diameter of the aneurysm was determined via computed tomography angiography. CTA and 
blood measurements were conducted every six months. Based on 5 AAA patients, nine 6-month 
monitoring periods were performed. 
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Overall, the aortic diameter significantly increased in AAA monitoring patients over time. At the first 
measurement the median diameter was 53.9 mm (36.7 mm to 62.8 mm) while 6 months later the 
median diameter measured 56.5 mm (38.2 mm to 64.3 mm, p=0.007). In contrast, the concentration of 
MPO-histone protein complexes decreased significantly during the monitoring period. At the first time 
point a median of 15.5 RU (6.3 RU to 20.8 RU) and at the second time point a median of 12.2 RU (6.3 RU 
to 20.3 RU; p=0.008) was determined. The other explorative variables did not differ significantly 
between time points. 
Parameter Time point (1) Time point (2) Difference p-value N 
 Median (min-max) Median (min-max)    
AAA diameter (mm) 53.9 (36.7-62.8) 56.5 (38.2-64.3) 1.5 (0.7-6.4) 0.007 9 
DNA–histone (RU) 11.8 (4.8-18.0) 11.8 (5.6-19.4) 0.3 (-6.1-7.7) 0.401 9 
CitH3 (ng/ml) 32.8 (21.1-138.38) 45.3 (19.5-184.8) 1.7 (-22.9-18.1) 0.594 9 
MPO-histone (RU) 15.5 (6.3-20.8) 12.2 (6.3-20.3) -0.4 (-4.5-3.1) 0.008 9 
MPO (ng/ml) 58.9 (9.3-235.3) 128.2 (9.3-249.3) 0.3(-66.4-78.0) 0.374 9 
 Table 8: Explorative parameters in AAA monitoring.                      
Abbreviations. MPO, myeloperoxidase. citH3, citrullinated histone 3. AAA, abdominal aortic aneurysm. RU, relative unites. 
 
                                                     5.1.2.3. Laboratory parameters  
Apart from comparing the explorative parameters for NETosis between the two time points, common 
laboratory parameters were of interest to detect potential co-morbidities associated with AAA 
progression.  
There was no significant difference between the two time points with regard to levels of free 
hemoglobin, lymphocytes, erythrocytes, monocytes, leukocytes, neutrophils, platelets  mean 
thrombocyte volume, pancreatic amylase, alpha amylase, c-reactive protein, high density lipoprotein, 
total cholesterol, triglycerides, albumin, urea, creatinine, D-dimer and activated partial thromboplastin 
time. However, at the later time point of investigation concentrations of 24-hydroxyvitamin D were 
elevated (p=0.051), while fibrinogen levels (p=0.051), low density lipoprotein levels (p=0.028), and the 
cholesterol/high density lipoprotein ratio (p=0.015) were lowered (Table 9). 
At time point one 24-hydroxyvitamin D levels were at a median of 50.3 nmol/l (24.8 nmol/l to 101.0 
nmol/l) whereas the samples at time point two displayed a median of 75.0 nmol/l (24.8 nmol/l to 115.0 
nmol/l). Fibrinogen showed a median of 414.0 mg/dl (344.0 mg/dl to 648.0 mg/dl) at time point one 
while the follow-up samples had a median at 357.0 mg/dl (181.0 mg/dl to 421.0 mg/dl). Low density 
lipoprotein showed a median of 92.8 mg/dl (36.6 mg/dl to 181.0 mg/dl) at time point one while in the 
follow-up samples the median was at 74.4 mg/dl (36.6 mg/dl to 124.8 mg/dl). The cholesterol/high 
density lipoprotein ratio showed a median of 5.0 (3.5 to 7.3) at the first time point and 3.8 (3.0 to 5.1) 












Median (min-max)   






-10.7 (-80.2-3.2) 0.028 9 
Cholesterol/High density 
lipoprotein ratio 
5.0 (3.5-7.3) 3.8 (3.0-5.1) -1.1 (-2.2-0.3) 0.015 9 




-0.18 (-2.91-0.42) 0.286 9 
Platelets (10^3/µl) 146 (33-209) 179 (131-213) 17 (-22-100) 0.139 9 
Leukocytes (10^3/µl) 7.7 (4.1-10.3) 7.7 (6.4-14.3) 0.5 (-1.3-4.5) 0.286 9 
Neutrophils (10^3/µl) 4.6 (3.1-7.6) 5.7 (3.9-11.3) 0.2 (-0.7-4.1) 0.515 9 
Lymphocytes (%) 23 (10.2-35.3) 23.0 (13.6-
35.3) 
-1.2 (-6.3-11.2) 0.998 9 
Monocytes (%) 5.9 (3.6-14.2) 6.2 (4.0-11.2) -0.1 (-4.3-3.9) 0.859 9 




-0.2 (-8.7-8.4) 0.575 9 
C-reactive protein 
(mg/dl) 
0.48 (0.2-13.9) 0.22 (0.15-
1.46) 
-0.12 (-13.76-0.92) 0.477 9 
Mean thrombocyte 
volume 
10.4 (8.8-10.9) 10.5 (9.3-11.4) 0.1 (-0.2-0.5) 0.202 7 
Free hemoglobin (mg/dl) 3.1 (1.8-4.3) 3.4 (1.6-15.0) 0.9 (-0.8-11.7) 0.123 8 
Antithrombin III (%) 96 (91-116) 96 (87-113) -2.5 (-3-2) 0.194 4 
Activated partial 
thromboplastin time (s) 
3.55 (30-37) 33.5 (31.7-
41.1) 
1.0 (-2.5-4.1) 0.440 9 




-49.0 (-434.0-13.0) 0.051 9 
D-dimer (µg/ml) 1.32 (0.6-2.37) 1.47 (0.63-
2.27) 
-0.06 (-0.28-0.64) 1.000 4 




-24.0 (-124.0-40.0) 0.192 9 






5.0 (-14.0-33.0) 0.262 9 
Triglycerides (mg/dl) 241 (88-546) 215 (106-250) -19 (-359-47) 0.123 9 




-0.2 (-4.7-7.2) 0.944 9 




1.3 (-10.1-12.3) 0.722 9 




0.00 (-0.55-0.34) 1.000 9 
Pancreatic amylase (u/l) 15.5 (15-30) 15.5 (14-21) -1 (-9-1) 0.257 4 







9.4 (-4.7-64.7) 0.051 9 




                                           5.1.2.4. Prognostic Marker Evaluation for AAA Progression 
It was then assessed whether any of the investigated parameters at time point 1 could predict aneurysm 
growth (i.e. the difference in maximal aortic diameter) over the next 6 months. The analysis of common 
laboratory parameters showed that baseline levels of erythrocytes and high density lipoprotein levels 
were significantly correlated with AAA growth (Table 10). In fact, the difference in AAA diameter 
(between time point 2 and 1) correlated positively with the number of erythrocytes (R=0.712, p=0.031; 
Fig. 16A) and negatively with high density lipoprotein blood concentrations (R=-0.681, p=0.043; Fig. 
16B). 
There were no significant correlations between any of the other routine laboratory parameters and AAA 
progression. However, blood leukocytes, albumin and creatinine showed coefficients (rho) higher than 
0.4 which is generally qualified as moderate correlation. When patients and monitoring periods were 
grouped into slow (<2 mm/6 months) and fast (≥2 mm/6 months) aneurysm growth, only erythrocytes 
and albumin showed a trend towards higher levels at baseline in the fast progressors (Table 10). 
Regarding the explorative neutrophil-related parameters a negative correlation between citH3 and AAA 
growth (R=-0.729, p=0.026; Fig. 16C) was found, and slow/fast progressors differed in their citH3 
baseline values (p=0.050). 







Erythrocytes  (10^6/µl) 9 0.712 0.031 0.086 
High density lipoprotein (mg/dl) 9 -0.681 0.043 0.268 
Leukocytes (10^3/µl) 9 0.644 0.061 0.221 
Albumin (g/l) 9 0.533 0.122 0.065 
Creatinine (mg/dl) 9 -0.424 0.256 0.086 
CitH3 (ng/ml) 9 -0.729 0.026 0.050 
Mean thrombocyte volume 12 0.736 0.006  
Platelets (10^3/µl) 14 0.688 0.007  
Activated partial thromboplastin 
time (s) 
14 0.578 0.030  
Low density lipoprotein (mg/dl) 14 -0.490 0.075  
DNA–histone (RU) 14 -0.499 0.069  
Table 10: Prognostic marker value of laboratory parameters for AAA progression.             
















Figure 15: Correlations of blood parameters and AAA growth.                                                                         
The scatter diagrams illustrate the correlation between A) erythrocytes at baseline and subsequent AAA diameter 
progression, B) high density lipoprotein and C) citH3 levels at time point 1 and AAA diameter progression over the next 6 
months.                                                                                                                                                                                           
Abbreviations. citH3, citrullinated histone 3. AAA, abdominal aortic aneurysm.  
Furthermore, we tested for correlations among all explorative and laboratory parameters and the AAA 
diameter in the collected data set, independent of the time point of investigation. 
Analyses revealed significant positive correlations between maximal aortic diameter and the activated 
partial thromboplastin time (R=0.578, p=0.030, Fig. 17A), mean thrombocyte volume (R=0.736, p=0.006; 
Fig. 17B) and platelet counts (R=0.688, p=0.007; Fig. 17C). AAA diameter and blood levels of low density 
lipoprotein (R=-0.490, p=0.075) or DNA-histone complexes (R=-0.499, p=0.069) correlated negatively. 
     









Figure 16: Correlation between AAA diameter and laboratory parameters (irrespective of time 
point of investigation).                                                                                                                                                    
The scatter diagrams illustrate the correlation of AAA diameter and A) activated thromboplastin time, B) mean 
thrombocyte volume and C) platelets.                                                                                                                                                                   
Abbreviations. AAA, abdominal aortic aneurysm. 
Next, the question was addressed whether there was a correlation between any of the explorative and 
laboratory parameter values established at the two time points (Table 11). 
Significant correlations could be detected between neutrophil concentrations and D-dimer (R=-0.842, 
p=0.002), creatinine (R=0.576, p=0.031), urea (R=0.605, p=0.022), low density lipoprotein (R=-0.675, 
p=0.008) and mean thrombocyte volume (R=0.739, p=0.006). Analyses revealed also that citH3 levels 
correlated significantly with 25-hydroxyvitamin D (R=0.635, p=0.015), creatinine (R=-0.627, p=0.016), 
urea (R=-0.638, p=0.014) and free hemoglobin (R=0.687, p=0.010). In addition, a significant correlation 
was determined between MPO and 25-hydroxyvitamine D (R=-0.565, p=0.035), creatinine (R=0.640, 
p=0.014), urea (R=0.678, p=0.008), low density lipoprotein (R=-0.578, p=0.030) and mean thrombocyte 
volume (R=0.578, p=0.049).  Furthermore, MPO-histone complexes correlated significantly with D-
dimer (R=-0.673, p=0.033), 25-hydroxyvitamin D (R=-0.723 p=0.003), creatinine (R=0.625, p=0.017) and 
urea (R=0.532, p=0.050). Finally, analysis detected a significant correlation between DNA-histone 
complexes and creatinine (R=-0.819, p<0.001) and urea (R=-0.706, p=0.005). 
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Parameter 1 Parameter 2 Rho p-value N 
Neutrophils (10^3/µl)     
 D-dimer (µg/ml) -0.842 0.002 10 
 Creatinine (mg/dl) 0.576 0.031 14 
 Urea (mg/dl) 0.605 0.022 14 
 Low density lipoprotein (mg/dl) -0.675 0.008 14 
 Mean thrombocyte volume 0.739 0.006 12 
CitH3 (ng/ml)     
 25-Hydroxyvitamin D (nmol/l) 0.635 0.015 14 
 Creatinine (mg/dl) -0.627 0.016 14 
 Urea (mg/dl) -0.638 0.014 14 
 Free hemoglobin (mg/dl) 0.687 0.010 13 
MPO (ng/ml)     
 25-Hydroxyvitamin D (nmol/l) -0.565 0.035 14 
 Creatinine (mg/dl) 0.640 0.014 14 
 Urea (mg/dl) 0.678 0.008 14 
 Low density lipoprotein (mg/dl) -0.578 0.030 14 
 Mean thrombocyte volume 0.578 0.049 12 
MPO-histone (RU)     
 D-dimer (µg/ml) -0.673 0.033 10 
 25-Hydroxyvitamin D (nmol/l) -0.723 0.003 14 
 Creatinine (mg/dl) 0.625 0.017 14 
 Urea (mg/dl) 0.532 0.050 14 
DNA–histone (RU)     
 Creatinine (mg/dl) -0.819 <0.001 14 
 Urea (mg/dl) -0.706 0.005 14 
Table 11: Correlations between explorative and clinical parameters in AAA monitoring.          
Abbreviations. MPO, myeloperoxidase. citH3, citrullinated histone 3. RU, relative unites.  
Regarding potential correlations among the neutrophil-related explorative parameters (Table 12) a 
significant association between citH3 and neutrophils (R=-0.609, p=0.003), MPO (R=-0.538, p=0.047) 
and MPO-histone complexes (R=-0.596, p=0.025) was detected. Furthermore, the analysis determined 
that MPO correlated significantly with neutrophil levels (R=0.723, p=0.003), MPO-histone complexes 
(R=0.864, p<0.000) and DNA-histone complexes (R=-0.726, p=0.003). Significant correlations were 
found also between blood concentrations of MPO-histone complexes and neutrophils (R=0.736, 
p=0.003) and DNA-histone complexes (R=-0.711, p=0.004). Finally, DNA-histone complexes and 
neutrophils (R=-0.640, p=0.014) and MPO-histone complexes (R=-0.711, p=0.004) were significantly 






Parameter 1 Parameter 2 Rho p-value N 
CitH3 (ng/ml)     
 Neutrophils (10^3/µl) -0.609 0.003 14 
 MPO (ng/ml) -0.538 0.047 14 
 MPO-histone (RU) -0.596 0.025 14 
MPO (ng/ml)     
 Neutrophils (10^3/µl) 0.723 0.003 14 
 MPO-histone (RU) 0.864 0.000 14 
 DNA–histone (RU) -0.726 0.003 14 
MPO-histone (RU)     
 Neutrophils (10^3/µl) 0.736 0.003 14 
 DNA–histone (RU) -0.711 0.004 14 
DNA–histone (RU)     
 Neutrophils (10^3/µl) -0.640 0.014 14 
 MPO-histone (RU) -0.711 0.004 14 
Table 12: Correlations among explorative parameters in AAA monitoring.     




















              5.2. Animal Study 
                 5.2.1. Optimization of DNA Release Assay 
Since the aim of AAA mouse studies was to test the therapeutic potential of anti-NET therapy, a simple 
and reliable assay to screen NET formation in isolated mouse neutrophils was warranted. NET induction 
in mouse blood is accompanied by an increase in cell-free DNA which can be measured by fluorescent 
DNA dyes. First, the optimal conditions for the DNA release assay had to be established. For this purpose 
it was of utmost importance to determine an effective dose of the calcium ionophore A23187 to induce 
maximal DNA release from neutrophilic granulocytes in vitro.   
Mouse blood was drawn from the vena cava and granulocytes were isolated with a commercial 
neutrophil enrichment kit. A23187 was applied at 0.25 µM, 0.5 µM, 1 µM, 2 µM and 4 µM and DNA 
release was measured by determining the relative fluorescence units (RFU) during a period of 165 min 
(Fig. 18). At 120 minutes moderate stimulation of DNA release could be observed at 0.25 µM (9.24 RFU), 
0.5 µM (17.48 RFU), and 1 µM (12.49 RFU) A23187 when compared to the untreated control (10.68 
RFU). However, A23187 showed a strong stimulatory effect at 2 µM (25.41 RFU at 120 minutes) and at 
4 µM (27.20 RFU at 120 minutes).  
It was also determined whether 2 mM of GSK484 had an impact on the basal DNA release and could 
block NET induction. Indeed, the addition of GSK484 reduced NET formation in response to 4 µM A23187 
(to 9.27 RFU at 120 min). 
 
 
Figure 17: Dose-response to A23187 with regard to NET stimulatory effect on neutrophilic 
granulocytes.                                                                                                                                                                                                            
Blood from five ApoE KO mice was drawn and pooled. Isolated neutrophils were pretreated with NET inhibitor GSK484 
for 30 min (where indicated), then stimulated in vitro by A23187 at 0.25 µM, 0.5 µM, 1 µM, 2 µM and 4 µM for 165 
minutes. DNA release by NETosis was monitored with Sytox Green incorporation and measurement of relative fluorescent 
units.                                                                                                                                                                                                                                                             



















































Next, the minimal number of neutrophilic granulocytes per assay was determined, since experimental 
mouse blood and neutrophil counts are limited. At first, 50.000 or 100.000 cells were added to each 96-
well. The cells were treated with 0 or 4 µM of A23187. The results of the DNA release assay showed that 
there was no considerable difference in background signal between the two cell concentrations in the 
untreated controls. When stimulated with A23187, the release of DNA was higher (57 RFU at 120 min) 
when applying 100.000 cells/well than with 50.000 cells/well (39 RFU). However, NET induction was 
clearly detectable with the lower cell concentration (Fig. 19). As a result, 50.000 cells per well were used 
for further experimentation.  
 
Figure 18: Determination of DNA release when using 50.000 or 100.000 neutrophilic granulocytes 
per assay.                                                                                                                                                                      
Three ApoE KO mice were treated with a single intravenous application of 200 µl PBS-/- (as negative control for 
subsequently conducted in vivo GSK484 administration in toxicity assays). Twenty-four hours later about 800 µl blood 
were taken from the vena cava inferior for the isolation of neutrophils. The isolated neutrophils were pooled. Either 
50.000 or 100.000 neutrophils per well were used. The cells were left untreated or stimulated with 4 µM of A23187 and 
the DNA release was measured.  
Abbreviations. RFU, relative fluorescent units.  
 
Next, it was tested whether ethanol (EtOH) or Hanks’ balanced salt solution (HBSS) was the optimal 
solvent for the NET inhibitor GSK484. In addition, the optimal concentration of GSK484 had to be 
determined. 
At 120 minutes the untreated neutrophilic granulocytes showed nearly no basal DNA release and an 
RFU value of only 1.62. The stimulatory effect of 4 µM of A23187 on DNA release (39.00 RFU) was as 
effective as a high dose of 133 µM A23187 (38.10 RFU), indicating saturation (Fig. 20B). This confirmed 
that 4 µM of A23187 was the optimal concentration to induce DNA release by mouse neutrophils in 
vitro. 
The NET inhibitor GSK484 was initially dissolved in EtOH. Aliquots of the stock were applied to obtain 
final concentrations of 3.2 µM, 16 µM, 80 µM, 400 µM and 2 mM. After 120 min of neutrophil treatment 





















































A23187 4µM 50000 Zellen
Untreated 100000 Zellen
A23187 4µM 100000 Zellen
Untreated 50000 cells 
A23187 4µM 50000 cells 
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A23187 were applied which raised the RFU close to 40. However, the combined treatment with 2 mM 
of GSK484 and A23187 lowered the RFU to 17.36, indicating that the inhibitory properties of GSK484 
were strong enough to suppress the A23187-induced DNA release. Lower concentrations of GSK484 led 
to a considerably weaker inhibition of the basal DNA release, e.g., at 120 minutes the RFU was 31.90 at 
3.2 µM of GSK484, 33.32 at 16 µM, and 22.88 at 80 µM (Fig. 20A). 
It remains to be elucidated why neutrophil treatment with 400 µM GSK484 and 4 µM of A23187 led to 
a somewhat higher DNA release (40.25 RFU at 120 minutes) than sole stimulation with 4 µM of A23187 
(39.00 RFU at 120 minutes).  
Next GSK484 was diluted in HBSS (Fig. 20B) and applied to obtain final assay concentrations of 3.2 µM, 
16 µM, 80 µM, 400 µM and 2 mM GSK484.  When compared to data obtained with EtOH-diluted GSK484, 
a somewhat arbitrary effect of this compound on the DNA release was observed at 120 min, i.e., at 3.2 
µM of GSK484 the RFU value was 26.91, at 16 µM 25.71 and at 80 µM 27.02. Importantly, it has to be 
noted that GSK484 precipitated in the HBSS stock.   
To conclude, it was decided to use 2 mM of GSK484, dissolved in EtOH, due its strong inhibitory effect 
on the A23187-induced DNA release. However, ethanol is known to be cytotoxic. As a consequence an 






















Figure 19: Dose-dependent inhibitory effects of GSK484 on A23187-induced DNA release by 
mouse neutrophils.                                                                                                                                                    
Three ApoE KO mice were treated with a single intravenous application of 200 µl PBS-/- (as negative control for 
subsequently conducted in vivo GSK484 administration in toxicity assays). Twenty-four hours later about 800 µl 
blood were drawn from the vena cava inferior for the isolation of neutrophils and isolated cells were pooled. Fifty 
thousand neutrophils were used per DNA release assay. In A) GSK484 was diluted in EtOH and in B) in HBSS prior to 
addition to assay wells. The cells were stimulated with 4 µM or 133 µM of A23187 (as indicated) and the DNA release 
was measured over 165 min.  
Abbreviations. RFU, relative fluorescent units. EtOH, ethanol. HBSS, Hank’s balanced salt solution.  
 
                                 5.2.2. GSK484 Toxicity and Dose Finding in Vivo  
The experience gained by experiments in vitro (see section 5.2.1.), had to be adapted to in vivo 
conditions for subsequent application in AAA mouse models. In a first approach, 200 µl PBS-/- were 
injected into the vena jugularis externa of ApoE KO mice in order to establish a control group for a more 
accurate comparison. After 24 hours blood was taken and DNA release was assayed with isolated mouse 
neutrophils. 
At 120 minutes the RFU of untreated controls was 0.9 and was raised to 39.8 by 4 µM A23187, indicating 
an approximately 40-fold stimulatory effect of A23187 (Fig. 21). Both, 2 mM of GSK484 and 2 mM of 
GSK484 plus 4 µM of A23187 led to RFU values around 13. This confirmed that neutrophilic 
granulocytes, obtained from PBS-treated animals, exhibited NET reactivity in vitro. Furthermore, in vitro 
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addition of GSK484 again suppressed DNA release effectively. However, it remained to be elucidated 
why GSK484 treatment alone caused the same level of DN 
A release as the combination treatment with A23187.  
 
Figure 20: DNA release by neutrophils from PBS treated control mice.                                                              
Two-hundred µl PBS-/- were injected into the vena jugularis externa of three ApoE KO mice. Twenty-four hours later 
about 500 µl blood were drawn from the vena cava inferior for the isolation of neutrophilic granulocytes. Due to lack of 
neutrophils the blood of the mice was pooled. The experiment was repeated a second time with two ApoE KO mice and 
blood was pooled. Data from the second experiment are being shown. Each time 50.000 neutrophils per well were used. 
GSK484 was diluted in EtOH and DNA release was stimulated with 4 µM A23187 over a time course of 165 min.  
Abbreviations. RFU, relative fluorescent units. EtOH, ethanol.  
Next, the optimal in vivo dose of GSK484 and possible adverse effects of this compound had to be 
determined. To start, the EtOH stock of GSK484 was diluted with 0.9% NaCl to reach 0.2 µg of GSK484 
/g mouse body weight in a total volume of 200 µl which were injected into the vena jugularis externa of 
ApoE KO mice. The veterinarians Anne Kramer and Katharina Tillmann of the local animal 
experimentation facility were contacted to inspect the animals. Mice showed barely any side effects. 
They were more active than usual and showed signs of slight abdominal pain. After 24 hours blood was 
drawn, neutrophils isolated and the DNA release assay was performed. 
At 120 minutes cells showed a basal RFU of 2.00, which was raised about 13-fold to 27.25 by 4 µM 
A23187 (Fig. 22). In comparison to the PBS-treated mice 40-fold stimulatory effect by 4 µM A23187) a 
reduction in DNA release was detectable (Fig. 21). Adding 2 mM of GSK484 in vitro further suppressed 
A23187-induced DNA release to 21.59 RFU at 120 minutes. Again, GSK484 exposure in vitro raised the 
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Figure 21: DNA release after in vivo application of GSK484 at 0.2 µg/g body weight.                                 
Injection of GSK484 0.2 µg/g bodyweight was performed into the vena jugularis externa of three ApoE KO mice. 24 hours 
later about 500 µl blood were drawn from the vena cava inferior for the isolation of neutrophils. Fifty thousand (pooled) 
neutrophils were used per assay. GSK484 was diluted in EtOH for in vivo and in vitro application. DNA release was 
stimulated in vitro with 4 µM A23187 over a time course of 165 min.                                                                                                       
Abbreviations. RFU, relative fluorescent units. EtOH, ethanol.  
 
As next step, the dose was elevated to 2.0 µg of GSK484/g body weight in order to achieve a more 
prominent inhibitory effect on the DNA release by NET formation. In addition, the in vitro concentration 
of A23187 was reduced to 1 and 2 µM in order to lower the magnitude of NET induction in the isolated 
neutrophils and possibly facilitate the detection of anti-NET effects by in vivo applied GSK484.  
Mice were inspected closely after GSK484 administration. Again no side effects, except for increased 
activity levels and mild abdominal pain, were noted. In the isolated neutrophilic granulocytes the basal 
RFU value of DNA release was 1.64 at 120 minutes (Fig. 23). A23187 induced NET formation dose-
dependently: 25.82 RFU at 1 µM, 32.29 RFU at 2 µM, and 34.33 RFU at 4 µM, indicating a 21-fold 
elevation. In vitro application of 2 mM GSK484 alone resulted in a slightly higher DNA release (15.28 
RFU) than the combination of 2 mM of GSK484 + 2 µM of A23187 (11.06 RFU). Surprisingly, 2.0 µg of 
GSK484/g body weight showed a weaker inhibitory effect on DNA release, induced by 4 µM of A23187 
(21-fold elevated compared to untreated control) than 0.2 µg of GSK484/g body weight (13-fold 
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Figure 22: DNA release after in vivo application of GSK484 at 2 µg/g mouse weight.                                    
Injection of 200 µl GSK484 at 2.0 µg/g body weight was performed into the vena jugularis externa of three ApoE KO mice. 
Twenty-four hours later about 500 µl blood were drawn from the vena cava inferior for the isolation of neutrophilic 
granulocytes. Mice were evaluated individually. GSK484 was diluted in EtOH for in vivo and in vitro application. DNA release 
was stimulated in vitro with 1, 2 or 4 µM A23187 over a time course of 165 min. The diagram shows the data of one individual 
animal.                                                                                                                                                                                                     
Abbreviations. RFU, relative fluorescent units.  
Finally the highest possible dose of GSK484 (based on solubility in EtOH) was tested in vivo and 20.0 µg 
of GSK484/g body weight were injected into the vena jugularis externa. The mice again showed barley 
any side effects. After 24 hours blood was drawn and DNA release was assayed in isolated neutrophilic 
granulocytes. Cells were only stimulated by 1.5 µM of A23187 due to the assumption that 4 µM was 
saturating and possibly too strong to detect the in vivo GSK484 inhibitory effects. At 120 minutes the 
RFU in the untreated cells was 3.4 and in the A23187 stimulated cells 19.9, indicating a 6-fold increased 
DNA release (Fig. 24). Surprisingly, in vitro addition of 2 mM of GSK484 alone led to a stronger DNA 
release (49.21 RFU) than 1.5 µM of A23187 or the combination of 2 mM of GSK484 with 1.5 µM of 



















































Figure 23: DNA release after in vivo application of GSK484 at 20 µg/g mouse weight.                                                        
GSK484 was injected at 20.0 µg/g body weight in 200 µl solvent into the vena jugularis externa of three ApoE KO mice. Twenty-four 
hours later about 900 µl blood were drawn from the vena cava inferior for the isolation of neutrophils. Fifty thousand pooled 
neutrophilic granulocytes were used per in vitro DNA release assay. GSK484 was diluted in EtOH for application in vitro and in vivo. 
DNA release by isolated neutrophils was stimulated with 1.5 µM A23187 over a time course of 165 min.                                                 
Abbreviations. RFU, relative fluorescent units.  
 
At the time of experimentation, data on the pharmacokinetics of this compound in mice were lacking. 
Therefore, it was tested whether the time period of 24 hours was too long for the inhibitor to still show a 
sufficient pharmacological effect.  
GSK484 was injected into the vena jugularis externa of three ApoE KO mice at a dose of 2.0 µg/g body 
weight. In addition, a new control group with saline injection (N=2) had to be generated. Blood samples 
were drawn already after 4 hours, mouse neutrophils were isolated. In the DNA release assay 2 µM of 
A23187 were applied (Fig. 25).  
At 120 minutes the untreated neutrophilic granulocytes of the new control group showed a similar DNA 
release (RFU 4.57) as the GSK484-pretreated group (6.26 RFU). However, when 2 µM of A23187 were 
applied in vitro, a stronger stimulatory effect was observed in the cells isolated from GSK484-pretreated 
mice (27.57) than from control animals (22.63 RFU). Based on these results it was suspected that (the 
reversible PAD4 inhibitor) GSK484 may be washed out during the isolation of the neutrophilic granulocytes 
from mouse blood and hence be ineffective during in vitro experiments. 
At 120 minutes the untreated cells of the GSK484-pretreated animals showed an RFU value of 6.26, which 
was raised to 27.57 RFU by 2 µM of A23187, indicating an about 4-fold increased DNA release. In vitro 
treatment of GSK484 was able to further lower the baseline RFU to 3.43. However, it remains unclear why 
a higher RFU of 37.19 was obtained by the combination of A23187 and GSK484 treatment as compared to 





















































Figure 24: DNA release based on GSK484 injection at 2.0 µg/g mouse weight and neutrophil isolation 
after four hours.                                                                                                                                                                         
A) 200 µl PBS-/- were injected into the vena jugularis externa of two ApoE KO mice, B) 2.0 µg GSK484/g body weight were 
injected into the vena jugularis externa of three ApoE KO mice. Four hours later about 600 µl of blood were drawn from the 
vena cava inferior for the isolation of neutrophils. Fifty thousand pooled neutrophils were used per assay. GSK484 was diluted 
in EtOH. DNA release by isolated neutrophils was stimulated with 2 µM A23187 over a time course of 165 min. 















The following table (Table 13) gives an overview on the DNA release of neutrophilic granulocytes 
obtained from ApoE KO mice depending on the different treatments in vivo as well as in vitro.  
 
   In vivo treatment  



































A23187 1 µM     26.33 
±5.09 
 
A23187 1.5 µM      19.54 
±4.54 






  23.79 
±12.11 
 








A23187 133 µM   38.90 
2.36 
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GSK484 2 mM+ 
A23187 1.5 µM 
     31.01 
±1.47 
GSK484 2 mM+ 





    
Table 13: Overview on DNA release assay results.                                                                                                                                                         
ApoE KO mice were injected either with 200 µl PBS-/- or GSK484 at the following concentrations: 0.2, 2.0 µg/g or 20.0 µg 
GSK484/g body weight. Depending on the setting blood was taken after 4 or 24 hours. The isolation of neutrophilic 
granulocytes and the DNA release assay were performed as described in Methods.  Means ± standard deviation were 
calculated for RFU values obtained at 120 minutes. Results obtained under the standard conditions of 4 µM A23187 and 2 
mM GSK484 are highlighted in blue color.                                                                                                                                                       
* after neutrophil isolation cells of the individual mice were pooled prior to assay initiation                                                             






In conclusion, it was decided not to proceed further with the isolation of neutrophilic granulocytes and 
DNA release assays to monitor in vivo effects on mouse neutrophils and their NETosis potential. It was 
assumed that the long isolation process of >6 hours, involving numerous washing steps, may lead to 
inactivation and removal of GSK484 from mouse blood and mouse neutrophils. In addition, the half-life 
of GSK484 in ApoE KO mice was unknown and it appeared possible that the experiments required too 
much time for the substance to show its full inhibitory effect. Furthermore, it remained to be elucidated 
why the combined treatment with A23187 and GSK484 led to paradox results in the in vitro DNA release 
assay. Hence, ex vivo testing of mouse blood for NETosis potential was switched to blood smears. 
5.2.3. NET Formation in Blood Smears 
For this assay, blood samples were drawn from ApoE KO mice with angiotensin II-induced AAA.  To be 
more specific, animals received a subcutaneous osmotic pump releasing AngII over a time frame of 28 
days which resulted in aneurysm formation. At day 14, expansion of the aortic diameter was verified by 
ultrasound and an intravenous catheter was inserted into the vena jugularis externa, connected to a 
subcutaneous mouse port for serial access. Mice were treated daily with a single injection of 200 µl PBS-
/- (controls) or 200 µl of PBS containing 2.0 µg of GSK484/g body weight via the port chamber. On day 
28 of the experiment the aortic diameter was again assessed by ultrasound and mice were euthanized 
to obtain blood from the vena cava inferior. Aliquots of blood were used immediately for in vitro NET 
induction by A23187 (50, 200 and 500 µM) over 2 hours. Blood smears were generated and stained to 
identify leukocytes by Hoechst-positive nuclei, neutrophilic granulocytes by Ly6G-positive 
immunostaining and NETs by Hoechst-positive fragmented nuclei (early stage) or DNA strings (late 
stage) with citH4 staining. Cells were counted under the confocal microscope in comparable field views.  
Figure 26 shows representative confocal pictures of blood smears from one control mouse.  
When no A23187 was added hardly any NETosis was observed. Stimulation with 50 µM of A23187 led 
to formation of small fragmented cells. Stimulation with 200 µM and 500 µM A23187 resulted in the 
formation of elongated NETs (strings), who appeared like string-like structure extending from the cell 
body. 
Interestingly, only the stimulation with 500 µM A23187 resulted in prominent staining with anti-
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Figure 25: Confocal images of immunofluorescence-stained blood smears of a control treated AAA 
mouse. 
Blood was drawn from a PBS-treated ApoE KO mouse with aneurysm induction by AngII. Blood aliquots were stimulated in 
vitro with 0, 50, 200 or 500 µM of A23187 for two hours to induce DNA release. Smears of the samples were triple-stained 
for DNA with Hoechst dye (in blue), for the neutrophil surface marker LyG6 (in green), and  for citrullinated histone H4 (in 
red). Yellow rectangles indicate fragmented cells and white arrowheads point to formed NETs, appearing as string-like 
structures extending from the remnant cell body. Magnification: 63x using 1.4 Plan-Apochromat, oil, DIC; scale bar: 20 
µM. 





Figure 27 shows representative confocal pictures of blood smears from one ApoE KO mouse receiving 
daily injections of 2.0 µg of GSK484/g body weight. When no A23187 was added, NETosis was not 
observed. Stimulation with 50 µM of A23187 led to less formation of small fragmented cells in 
comparison to blood from the control-treated mouse (Fig. 26). Stimulation with 200 µM and 500 µM 
A23187 resulted in the formation of a few NETs. However, hardly any string-like structures were 
detected. In addition, A23187-stimulated cells from the GSK484 treated mouse did not reveal any 
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Figure 26: Confocal images of immunofluorescence-stained blood smears of an AAA mouse treated 
with 2.0 µg of GSK484/g body weight.                                                                                                                                                                                   
Blood was drawn from a GSK484-treated ApoE KO mouse with aneurysm induction by AngII. Aliquots were stimulated in 
vitro with 0, 50, 200 or 500 µM of A23187 for two hours to induce DNA release. Smears of the blood samples were triple-
stained by Hoechst dye (in blue) and anti-LyG6 antibody (in green), and anti-citrullinated histone H4 antibody (in red). Yellow 
rectangles indicate fragmented cells and white arrowheads point to NETs, appearing as string-like structure extending from 
the remaining cell body. Magnification: 63x using 1.4 Plan-Apochromat, oil, DIC; scale bar: 20 µM.  






As the next step, the occurrence of NETs in the blood smears was evaluated in quantitative terms, i.e., 
the percentages of NETs was determined in relation to intact white blood cells (WBC) and neutrophilic 
granulocytes without and with stimulation of DNA release by A23187. It is important to note that NET 
frequency could exceed 100% when NET counts were higher than counts of intact leukocytes or 
neutrophils (set to 100%). 
Table 14 summarizes the relative frequency of NETs in blood smears from control-treated AAA mice 
(N=10). NETs occurred at 0.5% of WBC and at 3.5% of the population of neutrophilic granulocytes. 
Stimulation by A23187 caused a dose-dependent increase to 43% of WBC (at 500 µM) and 134% of the 
neutrophils (500 µM). At 50 µM of A23187 early stages of NETs were predominant, while 500 and 1000 
µM of A23187 resulted mostly in the formation of DNA strings (not shown). Furthermore, it has to be 
noted that the higher the A23187 concentration, the fewer intact cells were countable. The highest dose 
of A23187 (1 mM) was only tested in control-treated AAA mice, gave aberrant results and was hence 
omitted from the standardized assay in further experiments. 
When compared to control-treated AAA mice, GSK484 administration did not alter the basal frequency 
of NETs in the blood smears (Table 15). Treatment of mice with GSK484 reduced NETosis (in terms of 
mean NET frequency) of WBC stimulated by 50 µM or 200 µM of A23187, and led to a nearly significant 
(p=0.053) reduction at 500 µM (Fig. 28). In addition, GSK484 treatment reduced significantly (p=0.014) 
NETs of neutrophils, stimulated by 50 µM of A23187, and exerted a nearly significant effect (p=0.077) 
at 500 µM of A23187. In addition, the occurrence of late stages (strings) was reduced in all treatment 
groups (data not shown). 
 














mean  0.73 2.84 6.22 13.62 1.96 9.56 14.40 41.20 
min 0.00 0.00 3.39 0.00 0.00 0.00 6.06 0.00 
max 2.30 6.72 9.38 27.47 5.56 27.78 20.55 194.17 
SD 0.94 3.00 2.33 12.23 2.27 11.76 6.30 49.27 
Table 15: Effect of A23187 on the formation of NETs in AAA mice treated with GSK484 at 2.0 µg/g 
body weight. (N=5)                   
Abbreviations. GSK, GSK484. SD, standard deviation. NETs, neutrophil extracellular traps. 
 % NETs of white blood cells % NETs of neutrophils 
















mean  0.51 5.14 10.02 42.95 16.00 3.48 39.57 91.72 133.66 168.16 
SD 0.42 2.85 10.40 21.58 11.44 3.46 30.66 114.46 69.62 84.88 
Min 0.00 2.29 0.50 22.78 2.80 0.00 8.89 5.00 71.88 24.50 
max 1.35 12.15 33.33 65.71 28.57 10.00 108.33 366.67 120.00 230.77 
Table 14: Effect of A23187 on the relative frequency of NETs in blood smears of control-treated AAA 
mice. (N=10) 









Figure 27:  Dose-dependent effect of A23187 on NETosis in blood samples obtained from control 
or GSK484-treated AAA mice.                                                                      
Blood samples obtained from control-treated mice (N=10; blue) and mice treated with 2.0 µg of GSK484/g body weight 
(N=5; red) were stimulated for 2 h with A23187 at increasing concentration. Blood smears were generated, 
immunofluorescence staining was performed and NET counts determined in relation to intact cells. Box blots A) and B) 
show the percentage of NETs in relation to total white blood cells, while C) and D) show the percentage of NETs of 
neutrophilic granulocytes. 
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5.2.4. AAA Formation in Mice 
Seventeen ApoE KO mice were randomly assigned to two groups. The aorta was screened by ultrasound 
and no signs of AAA formation were obtained before start of treatment (Tables 16 and 17). As described 
previously, angiotensin II was applied via mini-pumps over a period of 14 days to generate the AAA in 
the suprarenal region. Five animals died of aneurysm rupture within this period. The area of AAA at its 
maximal diameter was determined by ultrasound at regular intervals, as described in the Methods. At 
day 14 post start of angiotensin II treatment there was no significant difference in area or diameter of 
any AAA region between the two treatment groups (Table 18).  
On day 14 portal chambers were implanted, which caused the loss of 3 animals. Then, treatment was 
randomly started with either PBS (for control) or  2.0 µg of GSK484/g body weight for further 14 days. 
On day 28 ultrasound screening was again performed to evaluate a potential therapeutic effect of 
GK484 treatment. However, none of the recorded parameters of aorta dimensions revealed a significant 
difference between the control mice and those which had been subjected to anti-NET therapy (Tables 
16, 17, 18 and Figures 29 and 30).  
Parameter Baseline 
Mean (min-max) 














area (mm3)   
0.909 
(0.761-1.066) 
0.12   5 1.107 
(0.874-1.321) 
0.19   5 1.590 
(1.364-1.746) 







0.07   5 1.198 
(0.991-1.297) 
0.14   4 1.486 
(1.286-1.777) 








0.11   5 1.093 
(0.734-1.508) 










0.15   5 1.585 
(1.160-2.174) 
0.37   5 1.647 
(1.137-2.684) 
0.61  5 
Table 16: Measurement of aorta by ultrasound in control AAA mice treated with saline.  
Baseline ultrasound measurements were performed on day 0 before start of angiotensin II treatment. The second ultrasound 
was conducted on day 14, when daily treatment with 200 µl PBS per animal was started. On day 28 the final ultrasound was 
performed. Data are expressed as mean and standard deviation. For further information see Methods. 
 
Table 17 shows an overview of aorta ultrasound measurements recorded of mice treated with GSK484 






















area (mm3)   
0.843 
(0.752-0.967) 
0.11   5 1.427 
(0.857-2.081) 
0.46   5 1.939 
(0.921-3.160) 







0.05   5 1.246 
(1.015-1.452) 
0.20   5 1.568 
(1.095-2.210) 








0.04   5 1.047 
(0.983-1.306) 
0.15   5 1.107 
(0.958-1.459) 








0.22   5 1.409 
(1.045-1.648) 
0.23   5 1.694 
(1.430-1.973) 
0.26  5 
Table 17: Measurement of aorta by ultrasound in AAA mice treated daily with 2.0 µg of GSK484/g body 
weight.   
Baseline ultrasound measurements were performed on day 0 before start of angiotensin II treatment. The second ultrasound was 
conducted on day 14, when daily treatments with 2.0 µg of GSK484/g body weight were started. On day 28 the final ultrasound was 





      N         
(C)        (G) 
Day 14 
p-value 
       N 
(C)        (G) 
Day 28 
p-value 
     N 
(C)    G) 
Mean 
suprarenal 
area (mm3)   








long axis view 




long axis view 
0.465 5              5 0.465  5             5 0.347 5          5 
Table 18: Statistical analysis of data obtained by ultrasound measurements of the aorta in control 
mice (C) and GSK484 (G) treated mice.                                                                                                                         
Statistical analysis was conducted with the Mann-Whitney-U-Test. 
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Figure 28: Ultrasound measurements of AAA mice treated with GSK484 or saline for negative 
control.  
The boxplots illustrate the measurements that were conducted at the following regions of the abdominal aorta: A) mean 
suprarenal area (mm3) in short axis view, B) mean suprarenal diameter (mm) in short axis view, C) mean infrarenal 
diameter (mm) in long axis view, and D) mean suprarenal diameter (mm) in long axis view. 
 
Figure 30 shows representative ultrasound images of AAA formation. The baseline ultrasound of the 
abdominal aorta in short axis view is given in A (diameter = 0.761 mm). On day 14 an increase in 









Figure 29: Ultrasound images of the abdominal aorta of a control-treated AAA mouse. 
Assessment of the diameter and area of the abdominal aorta using (A) short axis B mode at baseline, (B) short axis B mode and 
(C) long axis B mode 14 days after angiotensin II pump implantation. The diameter and area were measured during systole. 
Tracing was performed using the built-in Vevo 2100 software. Measurements were conducted from the outer aortic wall on one 
















The first aim of this study was to determine levels of NETosis markers in peripheral blood of AAA patients 
during monitoring and pre- and post-surgery. It was hypothesized that NET marker levels in the pre-
surgery phase would be associated with aneurysm progression, might hence predict AAA growth and 
should drop after surgical repair. In addition, the selective PAD4 inhibitor GSK484 was tested as 
potential pharmaceutical treatment option in an experimental model of AAA formation.   
A few studies have addressed NETosis in patients with various diseases like systemic lupus 
erythematosus [167], chronic granulomatous disease [168] and vasculitis [169]. However, the role of 
NETs in the development and progression of AAA is less characterized. NETs are able to recruit platelets 
and neutrophils to the endothelium. This supported the hypothesis, that they may take part in the 
pathogenesis of thrombosis and the activation of the extrinsic and intrinsic coagulation pathways which 
has subsequently been confirmed [170, 171]. Also chronic bacterial infections may sustain a basal 
NETosis activity in the body which may trigger AAA formation, e.g., NETs may play a part in AAA 
development in conjunction with periodontitis [144]. However, up to date parameters indicating 
NETosis have not yet been investigated specifically in the context of AAA progression and repair which 
was the main subject of this study.  
Demographics 
Concerning the patient demographics in the present study on aneurysm progression and repair, 100% 
of all AAA patients were men, which reflects their elevated risk for this disease [11]. Several 
cardiovascular comorbidities have been linked to AAA formation [13, 14]. In our collective of cases, 
being investigated in the pre- and post-surgery phase, 85.7% suffered from hypertension, 100% from 
hyperlipidemia, 28.6% had experienced coronary artery disease and myocardial infarction and 28.6% 
were treated for diabetes mellitus type II. In the monitoring study the pattern of co-morbidities was 
similar, i.e., 60% showed hypertension, hyperlipidemia and diseased coronary arteries, 40% myocardial 
infarction and 20% diabetes mellitus type II. It has been reported that an increase in the diastolic blood 
pressure per 10 mm Hg is associated with an AAA expansion rate of 0.02 cm per year [20]. A different 
study did not confirm the correlation between hypertension and progression of the aortic diameter, but 
found a positive correlation between hypertension and the risk of rupture [23]. Interestingly, diabetes 
mellitus type II was found to be associated with a reduced risk of AAA formation. Recently it was 
reported that the oral antidiabetic metformin may exert a protective effect possibly by limiting 
inflammation and stimulating the production of extracellular matrix in the arterial wall [26].  
In our collective more than 80% of the patients were cigarette smokers. Smoking of tobacco products is 
known to be a central risk factor in the formation and progression of AAA [11, 191]. The odds for 
developing an AAA are correlating positively with the number of daily cigarettes and of overall pack 
years, e.g., men smoking more than 25 cigarettes per day have a 15-fold risk of developing an AAA when 
compared to non-smokers [19, 192]. Furthermore, current tobacco smoking results in a 0.05 cm increase 
in aneurysm growth per year [20] and the risk of rupturing is increased twofold [12]. Even after quitting 
the risk remains elevated which indicates that the adverse effects of tobacco smoking are largely 
irreversible [19].  Recently Tulgar et al. reported that the neutrophil-to-lymphocyte ratio increases with 
each pack year, indicating stimulation of the innate immune system and a pro-inflammatory state [192]. 
In fact, tobacco promotes AAA formation through triggering inflammation, which is based on the 
elevated release of cytokines, like TNFα and IL-1ß, from macrophages [22]. Nicotine also stimulates 
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MMP expression, which triggers proteolysis and apoptosis of SMCs [21, 22]. In our study 42.9% of the 
patients in the pre- and post-surgery group and 20% in the monitoring group suffered from chronic 
obstructive pulmonary disease. This disease is associated with smoking, elevated serum TNFα levels and 
an increased chemotaxis of circulating neutrophils towards IL-8 and leukotriene B4, indicating a 
systemic influence of smoking on neutrophil migration and activation [193].  
Laboratory parameters 
Hemostasis and fibrin destruction continuously occur at the site of the ILT. This may result in elevated 
levels of coagulation and fibrinolysis factors in the blood of AAA patients originating from the tissue of 
the ILT [89]. Most reports focused on fibrinogen, the fibrin degradation product D-dimer and on the 
thrombin-antithrombin III complex. In the present study D-dimer did not increase significantly in AAA 
patients during the monitoring period and there were also no changes in D-dimer levels in the pre- or 
post-surgery phase. However, a significant negative correlation between D-dimer and MPO-histone 
complexes (p=0.033) and neutrophils (p=0.002) was observed. These results indicate that D-dimer might 
not be associated with pro-inflammatory processes occurring in the AAA. Fibrinogen, however, tended 
to decrease throughout the monitoring period (p=0.051) almost reaching statistical significance.  
The findings of this study disagree partly with previous reports, e.g., in a meta-analysis fibrinogen, the 
fibrinogen degradation product D-dimer, and the thrombin-antithrombin III complex prevailed as 
diagnostic markers by correlating with the size of the AAA and of the ILT [91]. In 2011 Golledge et al. 
proposed that plasma D-dimer may be a diagnostic and prognostic parameter for AAA progression [92]. 
Additional studies confirmed [194, 195] that D-dimer values correlate with the volume of the ILT as well 
as AAA diameter and have a high diagnostic value for the presence and prognostic value for the 
progression of the disease.  It was assumed that elevated plasma levels may be a result of the constant 
remodeling of fibrin in the ILT. As a consequence, elevated D-dimer levels are proposed to be associated 
with the destruction of the media in AAA which is promoted further by the ILT. It was also observed that 
fibrinogen levels were elevated years before an AAA had formed. This shows that deregulated 
hemostasis and fibrinolysis are involved in AAA pathogenesis at an early stage [93]. To conclude, our 
study did not confirm previous findings, which may be largely due to the low number of patients 
investigated.  
In 2018 Kubota et al. observed that elevated lipoprotein(a) blood levels were a risk factor for AAA 
development [196]. Further studies showed that increases in lipoprotein(a) may be due to gene 
polymorphisms of the lipoprotein receptor related protein 5 (LRP5) [197] and that a decreased 
expression of LRP5 in peripheral blood cells occurs in AAA patients. LRP5 encodes a transmembrane 
low-density lipoprotein receptor that binds and internalizes ligands in the process of receptor-mediated 
endocytosis and that may be involved in the regulation of lipoprotein(a) concentrations in blood. 
However, it remains to be investigated whether lipoprotein(a) may serve actually as prognostic marker 
for AAA. In the present study lipoprotein(a) levels significantly decreased (p=0.034) after surgery, which 
indicates again a putative significance of this protein in the pathogenesis of AAA. A weak negative 
correlation with the explorative parameter MPO was detected as well (p=0.032, Rho=-0.572). The 
significance of these findings remains to be elucidated in a larger collective of AAA patients. 
It has been observed that erythrocytes get trapped in the fibrin mesh of the ILT which leads to increased 
hemolysis [198]. Our study confirmed these observations, i.e., post-operative levels of erythrocytes 
were increased significantly (p=0.018), whereas free hemoglobin levels were decreased (p=0.028). 
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Furthermore, the percentage of lymphocytes dropped in the post-surgery phase (p=0.028) presumably 
due to repair of the locus of chronic inflammation by EVAR or OSR. Furthermore, in the pre- and post-
surgery cohort a positive correlation was evident between the percentage of lymphocytes and DNA-
histone complexes (p=0.056, Rho=0.521). This finding supports the hypothesis that neutrophils may be 
activated in the chronic inflammatory process of AAA and form NETs.  
It should further be noted that according to international recommendations [13], the AAA patients of 
the present study were treated with lipid-lowering drugs, e.g. statins and/or vitamin D. This regimen led 
to a significant decrease during the monitoring period in low density lipoprotein (p=0.028) and the 
cholesterol/high density lipoprotein ratio (p=0.015) and an increase in 25-hydroxyvitamin D levels 
(p=0.051). 
Explorative parameters 
AAA shows many characteristics of a chronic inflammatory disease and may serve as a site of neutrophil 
accumulation and formation of NETs. Furthermore, chronic inflammation at other sites in the body may 
sustain a basal NETosis activity and trigger AAA formation, such as the elevated risk for AAA in patients 
suffering from chronic periodontitis [144]. In this study by Delbosc et al., markers for NETs, like 
citrullinated histones and cell-free DNA (cfDNA), were elevated in the luminal part of the ILT and the 
adventitia of the AAA wall. In addition, the plasma of AAA patients contained more cell-free DNA and 
DNA-myeloperoxidase (MPO) complexes when compared to healthy controls. Likewise, in an 
experimental AAA model cfDNA and DNA-MPO complexes were elevated in the plasma [144].  Recently, 
further studies confirmed that NETs may indeed contribute to the pathogenesis of AAA irrespective of 
bacterial infections [175, 199, 200]. 
The formation of NETs involves activation of neutrophilic granulocytes. Ninety-five % of PMNs express 
MPO to generate ROS [56, 57]. In AAA patients, however, circulating PMNs show more MPO but less 
catalase activity than PMNs of healthy individuals, which indicates a gross imbalance towards a pro-
oxidative state [58]. These observations led to the idea that not only NETosis but also increased 
oxidative stress by activated neutrophilic granulocytes may be a main factor in the pathogenesis of AAA 
[58]. 
It is not fully established that NETosis is causally involved in AAA formation. The present study showed 
that circulating DNA-histone complexes (p=0.018), citH3 (p=0.043) and MPO (p=0.028) were decreased 
significantly after surgery. It remains unclear why MPO-histone complexes were not significantly 
altered. A positive correlation was shown between DNA-histone complexes and citH3 (p=0.003, 
Rho=0.732), DNA-histone complexes and MPO (p=0.017, Rho=0.626) and citH3 and MPO (p<0.001, 
Rho=0.868). These findings support the notion that all three parameters originate from the same source, 
namely activated neutrophils, and reinforce our hypothesis that NETs take an essential part in the 
pathogenesis of AAA. 
In a next step, patients suffering from AAA were subjected to a monitoring program, including computed 
tomography angiography of the abdominal aorta and analyses of serum and plasma samples every 6 
months, to evaluate which parameter may predict disease progression. Within the observation period 
the median diameter of the AAA increased significantly (p=0.007) from 53.9 mm to 56.5 mm. A non-
significant tendency towards increasing MPO (p=0.374) and citH3 (p=0.594) could be observed. It 
appears possible that a longer observation period is necessary to obtain clear results. The reasons for 
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the significant decrease in MPO-histone complexes (p=0.008) in the monitored patients remains to be 
elucidated.  
When baseline levels at the beginning of the monitoring period were compared with the change in AAA 
diameter over the next 6 months, the number of erythrocytes correlated positively with AAA 
progression (p=0.031, Rho=0.712). This finding challenges the assumption that red blood cells in 
circulation are reduced, as they get trapped in the fibrin mesh of the ILT  [198] and hence increase in 
the post-operative phase after aneurysm repair (p=0.018). However, higher erythrocyte counts may also 
be due to increased loss at the ILT site and subsequent erythropoiesis, in which case they would reflect 
a more active thrombus resulting in faster media destruction. HDL is known to have a cardiovascular 
protective effect. A meta-analysis showed that patients with AAA showed significantly lower HDL levels 
than healthy controls [201]. The present study supports and extends these findings, i.e. HDL levels 
correlated negatively with the expansion of the AAA diameter (p=0.043, Rho=-0.681). In contrast to our 
expectations, citH3 levels were associated negatively with disease progression (p=0.026, Rho=-0.729). 
This finding contradicts our hypothesis that NETs promote the progression of AAA. Therefore, one has 
to take into consideration the possibility that NETosis may also antagonize the formation and 
progression of AAA. In 2016 Bilyy et al. observed that NETs protected healthy pancreatic tissue against 
the formation of necrosis by forming a barrier [202]. Furthermore, in patients suffering from gout, 
aggregated NETs degraded pro-inflammatory cytokines and chemokines resulting in a decreased 
recruitment and activation of neutrophils [61]. These findings indicate that NETs may exert protective 
effects in several inflammatory diseases. 
To conclude, none of the explorative parameters evaluated at baseline showed the potential to predict 
disease progression, i.e. correlated positively with aneurysm growth. In contrast, the NET marker citH3 
correlated negatively. However, the significant decrease in DNA-histone complexes, citH3 and MPO 
post-surgery is strong evidence that NETosis indeed plays an essential role in the pathogenesis of AAA. 
Therefore, the formation of NETs may serve as target for pharmaceutical treatment.  
At the moment there is no selective pharmaceutical treatment option for AAA patients. Medication may 
slow down disease progression by reducing comorbidities but the only curative treatment is still surgical 
intervention [56]. The present study applied a rodent model to evaluate whether NETosis may serve as 
therapeutic AAA target. There are a number of different AAA animal models, like the elastase perfused 
rat model, the elastase perfused mouse model and the angiotensin II infused mouse model. However, 
not all of them mimic the risk factors of the disease and some do not even develop a thrombus [182-
185]. For this study the angiotensin II infused mouse model was used due to the fact that it mimics 
several human risk factors. Mice homozygous for the ApoE mutation develop hyperlipidemia. The 
treatment with angiotensin II leads to hypertension. The mice are of male gender. All these risk factors 
in combination play an important part during the pathogenesis of AAA. It also has been observed that 
angiotensin II infusion leads to an increased infiltration of macrophages resulting in a dilatation of the 
wall [186, 187]. In addition, this model generates an atherosclerotic lesion, luminal dilatation, medial 
degeneration, inflammation and intramural thrombus development. However, it has to be noted that 
the aneurysm forms suprarenal and the thrombus develops  intramural, whereas in humans most 
aneurysm are located infrarenal and the thrombus forms in the luminal part of the aorta [188]. 
Activation of protein kinase C (PKC) seems to play a key role in NET formation [203], i.e., PKCζ may 
activate PAD4 [155, 156], which is able to citrullinate the arginine of histones leading to a weakening of 
the electrostatic binding between histones and DNA [179]. Accordingly, it has been observed that PAD4 
75 
 
deficient mice are unable to form NETs [180]. In 2018 Meher et al. showed that treatment with a broad-
spectrum inhibitor of protein citrullination (Cl-amidine) attenuated AAA formation in an elastase-
induced AAA mouse model [204]. However, it was not determined whether this type of treatment was 
able to stop progression of an already established AAA.  
In the present study male ApoE KO mice received angiotensin II infusion via an osmotic pump. 
Ultrasound imaging showed that on day 14 of the treatment mice had developed an aortic dilatation, 
expanding from a mean baseline value of about 1 mm to 1.5 mm maximal suprarenal aortic diameter 
after two weeks. From day 14 on mice were treated daily with either PBS-/- (controls) or the selective 
PAD4 inhibitor GSK484 via an intravenous port system. GSK484 was tolerated well by the animals, as 
established by escalation of single doses. None of the animals died due to toxicity. Hence, a treatment 
dose of 2.0 µg GSK484 per g mouse weight was chosen.  
On day 28, blood samples were taken from animals in order to verify an inhibitory effect of GSK484 on 
the NETosis potential, quantified by the DNA release assay. As outlined in section 5.2.2 the results of 
this assay were inconclusive and difficult to reproduce. Thus, it was decided not to apply the neutrophil 
isolation and DNA release detection technique due to the assumption that the long isolation process of 
>6 hours, involving many washing steps, may not only wash out but also reverse the effect of GSK484, 
since it was described as selective but reversible PAD4 inhibitor. In future experiments, it would be 
useful to determine not only the pharmacokinetic profile of GSK484 in the living animal but also the 
stability of the compound in ex-vivo/in-vitro approaches in order to improve the evaluation of the 
therapeutic efficacy of this compound.   
As alternative and rapid approach to determine NETosis, aliquots of mouse blood samples were 
stimulated in vitro for 2 hours, then smeared and fixed and subsequently subjected to immunostaining 
and evaluation by confocal microscopy as outlined in section 4.2.10. To evaluate the reliability of this 
technique, setup experiments had to be performed. Isolated blood cells of control animals were 
stimulated in vitro with 0 µM, 50 µM, 200 µM, 500 µM and 1000 µM A23187, which increased NETosis 
dose-dependently, as determined by the above mentioned approach. Next, blood samples of GSK484-
treated animals were compared to those obtained from their untreated counterparts. There was a 
difference (of borderline significance) in the occurrence of NETs within the white blood cells between 
controls (42.95% NETs) and GSK484-treated mice (13.62% NETs) when cells were stimulated in vitro 
with 500 µM of A23187 (p=0.053). Furthermore, the frequency of NETosis in relation to intact 
neutrophils obtained with 50 µM of A23187 showed a significantly different (p=0.014) percentage of 
NETs in controls (39.57%) and GSK484-treated mouse blood (9.56%). In the control group the higher 
concentrations of A23187 resulted in the formation of DNA strings whereas the GSK484 treated cells 
showed rather early stages of NETosis in form of fragmented cells. These observations led to the 
interpretation that GSK484 may inhibit NETosis when stimulated with lower concentrations of A23187 
but may only delay the process when higher concentrations of A23187 are applied. Furthermore, these 
results indicate that the NETosis capacity was indeed reduced in the GSK484-treated animals, which led 
us to evaluate its effect on AAA progression as determined by ultrasound investigation of the suprarenal 
aortic diameter. In contrast to our hypothesis, the GSK484 treated group showed no significant 
difference in aneurysm expansion from day 14 to day 28, despite apparently reduced NETosis capacity. 
While the results are limited by the low number of animals investigated, they may also indicate that NET 
formation is not substantially involved in the progression of established disease but rather in the 
initiation/formation of aneurysms as indicated by previous reports [175, 204]. 
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NETosis may be involved not only in the formation of AAA but also in other pathophysiological 
processes. It has been published recently that subcutaneous GSK484 application reduced neuropathic 
pain in a rodent model [205]. Another study showed that GSK484 was able to treat cancer-associated 
kidney failure in an experimental model [206]. Furthermore, it has been observed that GSK484 is able 
to reduce angiogenesis induced by NET formation [207, 208].This is indication that death of neutrophils 
is occurring in many different diseases, thus stressing the fact that inhibitors of NETosis may have a 
broad therapeutic value. Thus, even though GSK484 had no significant effect on AAA progression in the 
applied mouse model, potential beneficial “side effects” on e.g. kidney disease associated with 
aneurysms may warrant further investigation. 
The present study has a number of strengths and weaknesses. Strengths include the novelty of using 
NETosis markers as laboratory parameters in AAA patients in the monitoring stage as well as in the pre- 
and post-surgery period. Secondly, it was demonstrated that intravenous treatment with PAD4 inhibitor 
GSK484 reduced the NETosis capacity in ApoE KO mice. This suggests that NETosis inhibition by GSK484 
may be tested in various disease settings involving NET formation. Third, a surgical approach of port 
implantation into the vena jugularis externa has been established in young mice. This new technique 
may be of considerable experimental value for repeated intravenous application of test compounds. 
On the other hand, the present work exhibits also several limitations. Designed as explorative study, 
the number of patients and animals investigated was rather small. Therefore, the results can hardly be 
compared to more comprehensive AAA studies [92]. Although the present work gives some indication 
that NETosis parameters correlate negatively with AAA progression in humans, this finding has to be 
confirmed in a larger collective of patients. Second, counting NETs under the confocal microscope has 
to be discussed when addressing weaknesses. Immunofluorescence staining is a recognized 
technology in visualizing NETs [190]  repeatedly counting the NETs yielded comparable results, which 
points towards consistency of the data acquired. However, the analysis has to be performed 
separately for each single blood smear which harbors a distinct potential of error. Thus, a standardized 
counting protocol performed by the same individual and re-evaluation of blinded samples by a second 
person should guarantee the reproducibility of the results. Third, none of the AAA mouse models 
covers all aspects of the human disease. It was shown recently that in one knock-out mouse strain two 
different AAA models showed opposite effects [199, 200, 209]. Therefore, the effectiveness of GSK484 
to inhibit aneurysm progression should be tested in additional AAA models, e.g. in mice with elastase-
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